

Seroconversion to Multiple Islet Autoantibodies and Risk of Diabetes in Children

JAMA - Journal of the American Medical Association

309, 2473

DOI: [10.1001/jama.2013.6285](https://doi.org/10.1001/jama.2013.6285)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Is there evidence for post-translational modification of beta cell autoantigens in the aetiology and pathogenesis of type 1 diabetes?. <i>Diabetologia</i> , 2013, 56, 2355-2358.	2.9	4
2	Environmental determinants of islet autoimmunity (ENDIA): a pregnancy to early life cohort study in children at-risk of type 1 diabetes. <i>BMC Pediatrics</i> , 2013, 13, 124.	0.7	59
3	The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. <i>Immunologic Research</i> , 2013, 57, 197-209.	1.3	76
4	The Evolution of Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2491.	3.8	10
5	Islet Autoantibody Testing: An End to the Trials and Tribulations?. <i>Diabetes</i> , 2013, 62, 4009-4011.	0.3	13
6	GAD65 Autoantibodies Detected by Electrochemiluminescence Assay Identify High Risk for Type 1 Diabetes. <i>Diabetes</i> , 2013, 62, 4174-4178.	0.3	82
7	Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1173-1183.	1.3	17
9	Following the Fate of the Failing β -Cell: New Insights From First-Phase Insulin Responses. <i>Diabetes</i> , 2013, 62, 3990-3992.	0.3	5
10	A Complex Role of Herpes Viruses in the Disease Process of Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e105434.	1.1	36
11	Innate Immune Activity Is Detected Prior to Seroconversion in Children With HLA-Conferred Type 1 Diabetes Susceptibility. <i>Diabetes</i> , 2014, 63, 2402-2414.	0.3	158
12	GAD Autoantibody Affinity in Adult Patients With Latent Autoimmune Diabetes, the Study Participants of a GAD65 Vaccination Trial. <i>Diabetes Care</i> , 2014, 37, 1675-1680.	4.3	39
13	Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. <i>Diabetes Care</i> , 2014, 37, 2034-2054.	4.3	727
14	Phases of type 1 diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2014, 15, 18-25.	1.2	48
15	Hydrolyzed Infant Formula and Early β -Cell Autoimmunity. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2279.	3.8	141
16	Update on the American Diabetes Association Standards of Medical Care. <i>Nurse Practitioner</i> , 2014, 39, 22-32.	0.2	18
17	Developing a vaccine for Type 1 diabetes through targeting enteroviral infections. <i>Expert Review of Vaccines</i> , 2014, 13, 989-999.	2.0	17
18	Definition, Classification and Diagnosis of Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 384-386.	0.6	470
19	Risk of Type 1 Diabetes Progression in Islet Autoantibody-Positive Children Can Be Further Stratified Using Expression Patterns of Multiple Genes Implicated in Peripheral Blood Lymphocyte Activation and Function. <i>Diabetes</i> , 2014, 63, 2506-2515.	0.3	32

#	ARTICLE	IF	CITATIONS
20	Mycobacteria, Immunoregulation, and Autoimmunity. , 2014, , 1-26.		0
21	Controlling the Metabolic Roller Coaster in Diabetes. JAMA - Journal of the American Medical Association, 2014, 311, 2277.	3.8	0
22	Characteristics and Determinants of Partial Remission in Children with Type 1 Diabetes Using the Insulin-Dose-Adjusted A1C Definition. Journal of Diabetes Research, 2014, 2014, 1-7.	1.0	32
23	A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion. Acta Diabetologica, 2014, 51, 403-411.	1.2	20
24	Prevalence of vitamin D deficiency in pre-type 1 diabetes and its association with disease progression. Diabetologia, 2014, 57, 902-908.	2.9	60
25	Compromised Gut Microbiota Networks in Children With Anti-Islet Cell Autoimmunity. Diabetes, 2014, 63, 2006-2014.	0.3	154
26	Autoimmune (Type 1) Diabetes. , 2014, , 575-586.		0
27	Prevention of Autoimmune Disease. , 2014, , 1191-1208.		0
28	A Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes. Diabetes, 2014, 63, 2538-2550.	0.3	261
29	Antigen Presentation in the Autoimmune Diabetes of the NOD Mouse. Annual Review of Immunology, 2014, 32, 579-608.	9.5	49
30	Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clinical and Experimental Immunology, 2014, 177, 571-585.	1.1	55
32	Islet Autoantibodies and Type 1 Diabetes: Does the Evidence Support Screening?. Clinical Chemistry, 2014, 60, 438-440.	1.5	6
33	What is type 1 diabetes?. Medicine, 2014, 42, 682-686.	0.2	3
34	Characterizing Subgroups of Type 1 Diabetes. Diabetes, 2014, 63, 3578-3580.	0.3	10
35	Lessons from Type 1 Diabetes for Understanding Natural History and Prevention of Autoimmune Disease. Rheumatic Disease Clinics of North America, 2014, 40, 797-811.	0.8	16
36	Trials in the Prevention of Type 1 Diabetes: Current and Future. Canadian Journal of Diabetes, 2014, 38, 279-284.	0.4	13
37	Preclinical Inflammatory Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2014, 40, 569-580.	0.8	29
39	GAD autoantibody affinity in schoolchildren from the general population. Diabetologia, 2014, 57, 1911-1918.	2.9	22

#	ARTICLE	IF	CITATIONS
40	Standards of Medical Care in Diabetes—2014. <i>Diabetes Care</i> , 2014, 37, S14-S80.	4.3	3,893
41	Role of Viruses and Other Microbes in the Pathogenesis of Type 1 Diabetes. <i>International Reviews of Immunology</i> , 2014, 33, 284-295.	1.5	51
42	Definition, epidemiology, and classification of diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2014, 15, 4-17.	1.2	231
43	Early Hyperglycemia Detected by Continuous Glucose Monitoring in Children at Risk for Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2031-2033.	4.3	29
44	Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of disease. <i>Pediatric Diabetes</i> , 2014, 15, 162-174.	1.2	21
45	Can We Prevent Type 1 Diabetes?. <i>Current Diabetes Reports</i> , 2015, 15, 86.	1.7	4
46	New Insights and Biomarkers for Type 1 Diabetes: Review for <i>Scandinavian Journal of Immunology</i> . <i>Scandinavian Journal of Immunology</i> , 2015, 82, 244-253.	1.3	11
47	A 3D map of the islet routes throughout the healthy human pancreas. <i>Scientific Reports</i> , 2015, 5, 14634.	1.6	149
48	Nieuwe inzichten in therapeutische mogelijkheden bij diabetes mellitus type 1. <i>Tijdschrift Voor Kindergeneeskunde</i> , 2015, 83, 9-17.	0.0	0
49	Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. <i>Diabetes Care</i> , 2015, 38, 1975-1985.	4.3	68
50	Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention. <i>Pediatric Diabetes</i> , 2015, 16, 465-484.	1.2	59
51	What defines disease in an age of genetics and biomarkers?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 296-299.	1.2	2
52	Characterization of human organ donors testing positive for type 1 diabetes-associated autoantibodies. <i>Clinical and Experimental Immunology</i> , 2015, 182, 278-288.	1.1	35
53	General population screening for type 1 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 270-276.	1.2	39
54	Doubly Reactive INS IGF^2 Autoantibodies in Children with Newly Diagnosed Autoimmune (type 1) Diabetes. <i>Scandinavian Journal of Immunology</i> , 2015, 82, 361-369.	1.3	9
55	New Technology for Type 1 Diabetes. <i>Journal of Korean Diabetes</i> , 2015, 16, 123.	0.1	0
56	Evaluation of Candidate Biomarkers of Type 1 Diabetes via the Core for Assay Validation. <i>Biomarker Insights</i> , 2015, 10s4, BMI.S29697.	1.0	11
57	Thrombophilia Associated with Anti-DFS70 Autoantibodies. <i>PLoS ONE</i> , 2015, 10, e0138671.	1.1	17

#	ARTICLE	IF	CITATIONS
58	Diet, Microbiota and Immune System in Type 1 Diabetes Development and Evolution. <i>Nutrients</i> , 2015, 7, 9171-9184.	1.7	93
59	Care of diabetes in children and adolescents: controversies, changes, and consensus. <i>Lancet, The</i> , 2015, 385, 2096-2106.	6.3	83
60	Immunopathology of Celiac Disease. , 2015, , 1551-1572.		1
61	Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?. <i>Pharmacological Research</i> , 2015, 98, 3-8.	3.1	13
62	Predicting Type 1 Diabetes Using Biomarkers. <i>Diabetes Care</i> , 2015, 38, 989-996.	4.3	136
63	The Streetlight Effect—Is There Light at the End of the Tunnel?. <i>Diabetes</i> , 2015, 64, 1105-1107.	0.3	7
64	Plasmonic Chip Tackles Type 1 Diabetes Diagnosis. <i>Clinical Chemistry</i> , 2015, 61, 794-796.	1.5	2
65	OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis. <i>Diabetologia</i> , 2015, 58, 1787-1796.	2.9	32
66	Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM). <i>Autoimmunity Reviews</i> , 2015, 14, 781-797.	2.5	93
68	Islet Autoantibody Detection by Electrochemiluminescence (ECL) Assay. <i>Methods in Molecular Biology</i> , 2015, 1433, 85-91.	0.4	14
69	Lessons From Pancreas Transplantation in Type 1 Diabetes: Recurrence of Islet Autoimmunity. <i>Current Diabetes Reports</i> , 2015, 15, 121.	1.7	55
70	Molecular Interactions Governing Autoantigen Presentation in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2015, 15, 113.	1.7	16
71	Type 1 Diabetes: Current Perspectives. <i>Methods in Molecular Biology</i> , 2015, 1433, 1-9.	0.4	1
72	2. Classification and Diagnosis of Diabetes. <i>Diabetes Care</i> , 2015, 38, S8-S16.	4.3	1,471
73	The 6-year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. <i>Diabetologia</i> , 2015, 58, 980-987.	2.9	313
74	Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). <i>Diabetes Care</i> , 2015, 38, 808-813.	4.3	135
75	HbA1c Predicts Time to Diagnosis of Type 1 Diabetes in Children at Risk. <i>Diabetes</i> , 2015, 64, 1719-1727.	0.3	49
76	Tyrosine-Phosphatase and Glutamate-Decarboxylase Antibodies After Simultaneous Pancreas Kidney Transplantation: Do They Have an Impact on Pancreas Graft Survival?. <i>Transplantation Proceedings</i> , 2015, 47, 107-111.	0.3	1

#	ARTICLE	IF	CITATIONS
77	Hyperglycemic Clamp and Oral Glucose Tolerance Test for 3-Year Prediction of Clinical Onset in Persistently Autoantibody-Positive Offspring and Siblings of Type 1 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 551-560.	1.8	10
78	Electrochemiluminescence Assays for Insulin and Glutamic Acid Decarboxylase Autoantibodies Improve Prediction of Type 1 Diabetes Risk. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 119-127.	2.4	55
79	Serum Proteomes Distinguish Children Developing Type 1 Diabetes in a Cohort With HLA-Conferred Susceptibility. <i>Diabetes</i> , 2015, 64, 2265-2278.	0.3	46
80	The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes. <i>Cell Host and Microbe</i> , 2015, 17, 260-273.	5.1	1,008
81	Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2139-2144.	3.3	123
82	Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. <i>Diabetologia</i> , 2015, 58, 411-413.	2.9	29
83	Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention. <i>Acta Diabetologica</i> , 2015, 52, 473-481.	1.2	7
84	A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. <i>Diabetologia</i> , 2015, 58, 346-354.	2.9	41
85	Influenza A virus antibodies show no association with pancreatic islet autoantibodies in children genetically predisposed to type 1 diabetes. <i>Diabetologia</i> , 2015, 58, 2592-2595.	2.9	18
86	New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 252-257.	1.5	15
87	Primary prevention for type 1 diabetes mellitus?. <i>Nature Reviews Endocrinology</i> , 2015, 11, 451-452.	4.3	2
88	Non-HLA gene effects on the disease process of type 1 diabetes: From HLA susceptibility to overt disease. <i>Journal of Autoimmunity</i> , 2015, 61, 45-53.	3.0	50
89	Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray. <i>Immunotherapy</i> , 2015, 7, 163-174.	1.0	30
90	Heterogeneity in diabetes-associated autoantibodies and susceptibility to Type 1 diabetes: lessons for disease prevention. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 25-34.	1.2	0
91	Type 1 diabetes: A predictable disease. <i>World Journal of Diabetes</i> , 2015, 6, 380.	1.3	80
92	Effects of High-Dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1541.	3.8	174
93	Toward Primary Prevention of Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1520.	3.8	8
94	Immunogenicity of β^2 -cells for autologous transplantation in type 1 diabetes. <i>Pharmacological Research</i> , 2015, 98, 60-68.	3.1	11

#	ARTICLE	IF	CITATIONS
95	Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4429-4434.	3.3	62
98	Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. Diabetologia, 2015, 58, 2753-2764.	2.9	15
99	Reliable diagnosis of murine type 1 diabetes using a panel of autoantigens and "antigen surrogates" mounted onto a liquid array. Molecular BioSystems, 2015, 11, 3156-3163.	2.9	5
100	Heritability of thyroid peroxidase autoantibody levels in type 1 diabetes: evidence from discordant twin pairs. Diabetologia, 2015, 58, 2079-2086.	2.9	6
101	Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?. Current Diabetes Reports, 2015, 15, 115.	1.7	11
102	Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015, 38, 1964-1974.	4.3	690
103	Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes. Diabetologia, 2015, 58, 2317-2323.	2.9	71
104	Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community. Diabetes Technology and Therapeutics, 2015, 17, 649-656.	2.4	10
105	Expression profiling pre-diabetic mice to uncover drugs with clinical application to type 1 diabetes. Clinical and Translational Immunology, 2015, 4, e41.	1.7	2
106	Attenuated humoral responses in HLA-A*24-positive individuals at risk of type 1 diabetes. Diabetologia, 2015, 58, 2284-2287.	2.9	8
107	Relationships between major epitopes of the IA-2 autoantigen in Type 1 diabetes: Implications for determinant spreading. Clinical Immunology, 2015, 160, 226-236.	1.4	12
108	Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies. Genes and Immunity, 2015, 16, 541-551.	2.2	15
109	The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). Current Diabetes Reports, 2015, 15, 49.	1.7	14
110	Autoantibody-defined risk for Type 1 diabetes mellitus in a general population of schoolchildren: results of the Karlsburg Type 1 Diabetes Risk Study after 18 years. Diabetic Medicine, 2015, 32, 1008-1016.	1.2	13
111	Novel diagnostic and therapeutic approaches for autoimmune diabetes " A prime time to treat insulinitis as a disease. Clinical Immunology, 2015, 156, 109-118.	1.4	7
112	Neuropeptide Y is a minor autoantigen in newly diagnosed type 1 diabetes patients. Pediatric Diabetes, 2015, 16, 621-628.	1.2	7
113	Type 1 Diabetes. , 2016, , 159-167.		9
114	Diabetes mellitus in childhood: an emerging condition in the 21st century. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2016, 62, 594-601.	0.3	5

#	ARTICLE	IF	CITATIONS
115	Longitudinal Frequencies of Blood Leukocyte Subpopulations Differ between NOD and NOR Mice but Do Not Predict Diabetes in NOD Mice. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	5
116	Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio. <i>PLoS ONE</i> , 2016, 11, e0166702.	1.1	14
117	The role of islet antigen presenting cells and the presentation of insulin in the initiation of autoimmune diabetes in the <sc>NOD</sc> mouse. <i>Immunological Reviews</i> , 2016, 272, 183-201.	2.8	32
118	Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. <i>Gut</i> , 2016, 65, 1061-1069.	6.1	68
121	Endocrinopathies: Chronic Thyroiditis, Addison Disease, Pernicious Anemia, Graves' Disease, Diabetes, and Hypophysitis. , 2016, , 930-953.		0
122	Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin. <i>Scientific Reports</i> , 2016, 6, 32899.	1.6	35
123	Viral infections in type 1 diabetes mellitus â€” why the Î² cells?. <i>Nature Reviews Endocrinology</i> , 2016, 12, 263-273.	4.3	232
124	Discovery of Phosphorylated Peripherin as a Major Humoral Autoantigen in Type 1 Diabetes Mellitus. <i>Cell Chemical Biology</i> , 2016, 23, 618-628.	2.5	17
125	Primary prevention of beta-cell autoimmunity and type 1 diabetes â€” The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. <i>Molecular Metabolism</i> , 2016, 5, 255-262.	3.0	54
127	Analysis of antigen specific T cells in diabetes â€” Lessons from pre-clinical studies and early clinical trials. <i>Journal of Autoimmunity</i> , 2016, 71, 35-43.	3.0	15
128	Chemical Tools To Monitor and Manipulate Adaptive Immune Responses. <i>Journal of the American Chemical Society</i> , 2016, 138, 6076-6094.	6.6	15
129	Islet Autoantibodies. <i>Current Diabetes Reports</i> , 2016, 16, 53.	1.7	76
130	Ã‰tude Pre-POINT : effets immunologiques de lâ€™insuline orale Ã forte dose. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 65-66.	0.1	0
131	miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6659-E6668.	3.3	50
132	Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. <i>BMJ Open</i> , 2016, 6, e011144.	0.8	89
133	The progress of luminescent assay in clinical diagnosis and treatment of diabetes mellitus. <i>Journal of Electroanalytical Chemistry</i> , 2016, 781, 322-326.	1.9	2
134	ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 410-414.	2.4	25
135	Insulitis in the pathogenesis of type 1 diabetes. <i>Pediatric Diabetes</i> , 2016, 17, 31-36.	1.2	63

#	ARTICLE	IF	CITATIONS
136	Dysregulation of glucose metabolism in preclinical type 1 diabetes. <i>Pediatric Diabetes</i> , 2016, 17, 25-30.	1.2	27
137	Risk Factors for Type 1 Diabetes Recurrence in Immunosuppressed Recipients of Simultaneous Pancreas-Kidney Transplants. <i>American Journal of Transplantation</i> , 2016, 16, 235-245.	2.6	56
138	Continuous glucose monitoring and HbA1c in the evaluation of glucose metabolism in children at high risk for type 1 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 120, 89-96.	1.1	22
139	3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 687-693.	2.4	27
140	Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2016, 16, 97.	1.7	20
141	High-Throughput Screening in General Population for Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 674-676.	2.4	3
142	3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8. <i>Clinica Chimica Acta</i> , 2016, 462, 60-64.	0.5	25
143	Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?. <i>Diabetes Care</i> , 2016, 39, 1738-1744.	4.3	19
144	AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies. <i>Cell</i> , 2016, 166, 582-595.	13.5	228
145	Current and future efforts toward the prevention of type 1 diabetes. <i>Pediatric Diabetes</i> , 2016, 17, 78-86.	1.2	19
146	Effects of the genome on immune regulation in type 1 diabetes. <i>Pediatric Diabetes</i> , 2016, 17, 37-42.	1.2	10
147	A Swedish approach to the prevention of type 1 diabetes. <i>Pediatric Diabetes</i> , 2016, 17, 73-77.	1.2	20
148	JDRF's vision and strategy for prevention of type 1 diabetes. <i>Pediatric Diabetes</i> , 2016, 17, 87-92.	1.2	14
149	Role of humoral beta-cell autoimmunity in type 1 diabetes. <i>Pediatric Diabetes</i> , 2016, 17, 17-24.	1.2	27
150	Early signs of disease in type 1 diabetes. <i>Pediatric Diabetes</i> , 2016, 17, 43-48.	1.2	11
151	A novel approach for the analysis of longitudinal profiles reveals delayed progression to type 1 diabetes in a subgroup of multiple-islet-autoantibody-positive children. <i>Diabetologia</i> , 2016, 59, 2172-2180.	2.9	38
152	Metabolomic Biomarkers in the Progression to Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2016, 16, 127.	1.7	11
153	Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study. <i>Scientific Reports</i> , 2016, 6, 31479.	1.6	134

#	ARTICLE	IF	CITATIONS
155	Type 1 diabetes vaccine candidates promote human Foxp3+Treg induction in humanized mice. <i>Nature Communications</i> , 2016, 7, 10991.	5.8	99
156	Type 1 Diabetes Prevention: A Goal Dependent on Accepting a Diagnosis of an Asymptomatic Disease. <i>Diabetes</i> , 2016, 65, 3233-3239.	0.3	20
157	Biomarkers in pancreas transplant. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 412-418.	0.8	5
159	Staging the progression to type 1 diabetes with prediagnostic markers. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 297-305.	1.2	12
160	Reversion of β -Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. <i>Diabetes Care</i> , 2016, 39, 1535-1542.	4.3	56
161	Follicular Helper T Cells in Autoimmunity. <i>Current Diabetes Reports</i> , 2016, 16, 75.	1.7	15
162	Fabrication of Biobased Polyelectrolyte Capsules and Their Application for Glucose-Triggered Insulin Delivery. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 13688-13697.	4.0	57
164	Environmental risk factors for type 1 diabetes. <i>Lancet, The</i> , 2016, 387, 2340-2348.	6.3	501
165	Genetic risk factors for type 1 diabetes. <i>Lancet, The</i> , 2016, 387, 2331-2339.	6.3	389
166	Predictors of slow progression to diabetes in children with multiple islet autoantibodies. <i>Journal of Autoimmunity</i> , 2016, 72, 113-117.	3.0	30
167	Validation of a rapid type 1 diabetes autoantibody screening assay for community-based screening of organ donors to identify subjects at increased risk for the disease. <i>Clinical and Experimental Immunology</i> , 2016, 185, 33-41.	1.1	38
168	Regulation of B lymphocyte responses to T -cell-like receptor ligand binding during diabetes prevention in non-obese diabetic (NOD) mice. <i>Journal of Diabetes</i> , 2016, 8, 120-131.	0.8	11
169	HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. <i>Diabetes</i> , 2016, 65, 1109-1119.	0.3	48
170	Reduced β -cell function in early preclinical type 1 diabetes. <i>European Journal of Endocrinology</i> , 2016, 174, 251-259.	1.9	34
171	A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease. <i>Journal of Immunological Methods</i> , 2016, 430, 28-32.	0.6	45
172	Expression-Based Genome-Wide Association Study Links Vitamin D-Binding Protein With Autoantigenicity in Type 1 Diabetes. <i>Diabetes</i> , 2016, 65, 1341-1349.	0.3	33
173	Growth and Risk for Islet Autoimmunity and Progression to Type 1 Diabetes in Early Childhood: The Environmental Determinants of Diabetes in the Young Study. <i>Diabetes</i> , 2016, 65, 1988-1995.	0.3	49
174	CD4 T cell differentiation in type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2015, 183, 16-29.	1.1	143

#	ARTICLE	IF	CITATIONS
175	Characterization of immune response to novel HLA-A2-restricted epitopes from zinc transporter 8 in type 1 diabetes. <i>Vaccine</i> , 2016, 34, 854-862.	1.7	19
176	Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes. <i>Diabetes</i> , 2016, 65, 1690-1698.	0.3	93
177	2. Classification and Diagnosis of Diabetes. <i>Diabetes Care</i> , 2016, 39, S13-S22.	4.3	917
178	Blood-based signatures in type 1 diabetes. <i>Diabetologia</i> , 2016, 59, 414-425.	2.9	48
179	Positivity for Zinc Transporter 8 Autoantibodies at Diagnosis Is Subsequently Associated With Reduced β -Cell Function and Higher Exogenous Insulin Requirement in Children and Adolescents With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 118-121.	4.3	28
180	The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. <i>Diabetologia</i> , 2016, 59, 542-549.	2.9	50
181	The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. <i>Journal of Autoimmunity</i> , 2016, 66, 76-88.	3.0	227
182	The case for an autoimmune aetiology of type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2016, 183, 8-15.	1.1	41
183	T cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review. <i>Journal of Autoimmunity</i> , 2016, 66, 7-16.	3.0	54
184	Modeling strategies to study metabolic pathways in progression to type 1 diabetes – Challenges and opportunities. <i>Archives of Biochemistry and Biophysics</i> , 2016, 589, 131-137.	1.4	13
185	Innate inflammation in type 1 diabetes. <i>Translational Research</i> , 2016, 167, 214-227.	2.2	65
186	Associations of growth patterns and islet autoimmunity in children with increased risk for type 1 diabetes: a functional analysis approach. <i>Pediatric Diabetes</i> , 2017, 18, 103-110.	1.2	15
187	Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. <i>Pediatric Diabetes</i> , 2017, 18, 794-802.	1.2	39
188	Increase in Pancreatic Proinsulin and Preservation of β -Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset. <i>Diabetes</i> , 2017, 66, 1334-1345.	0.3	83
189	Follicular T Helper Cells: A New Marker of Type 1 Diabetes Risk?. <i>Diabetes</i> , 2017, 66, 258-260.	0.3	9
190	Serum Trypsinogen Levels in Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 577-582.	4.3	40
191	Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study. <i>Diabetic Medicine</i> , 2017, 34, 934-937.	1.2	19
192	Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 591-610.	1.8	72

#	ARTICLE	IF	CITATIONS
193	A divergent population of autoantigen-responsive CD4 ⁺ T cells in infants prior to Î² cell autoimmunity. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	67
194	The association of the <i>HLA-A*24:02, B*39:01</i> and <i>B*39:06</i> alleles with type 1 diabetes is restricted to specific <i>HLA-DR/DQ</i> haplotypes in Finns. <i>Hla</i> , 2017, 89, 215-224.	0.4	23
195	Identification of Unique Antigenic Determinants in the Amino Terminus of IA-2 (ICA512) in Childhood and Adult Autoimmune Diabetes: New Biomarker Development. <i>Diabetes Care</i> , 2017, 40, 561-568.	4.3	30
196	The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 183-187.	2.4	21
197	The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes. <i>Diabetologia</i> , 2017, 60, 1185-1189.	2.9	32
198	Metabolite-Sensing G Protein-Coupled Receptors Facilitators of Diet-Related Immune Regulation. <i>Annual Review of Immunology</i> , 2017, 35, 371-402.	9.5	235
199	Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes. <i>Diabetologia</i> , 2017, 60, 1409-1422.	2.9	61
200	A1 beta-casein milk protein and other environmental pre-disposing factors for type 1 diabetes. <i>Nutrition and Diabetes</i> , 2017, 7, e274-e274.	1.5	55
201	Genetics and its potential to improve type 1 diabetes care. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 279-284.	1.2	17
202	Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children. <i>Diabetologia</i> , 2017, 60, 1467-1474.	2.9	37
203	Epigenetics and type 1 diabetes: mechanisms and translational applications. <i>Translational Research</i> , 2017, 185, 85-93.	2.2	40
204	T1D Autoantibodies. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 285-291.	1.2	17
205	Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility. <i>Diabetologia</i> , 2017, 60, 1284-1293.	2.9	29
206	Characteristics of the pre-diabetic period in children with high risk of type 1 diabetes recruited from the general Swedish populationâ€”The ABIS study. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2900.	1.7	12
207	Type 1 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17016.	18.1	790
208	Loss of Î²-cell mass â€” an acute event before T1DM presentation?. <i>Nature Reviews Endocrinology</i> , 2017, 13, 253-254.	4.3	7
209	Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. <i>Diabetes</i> , 2017, 66, 722-734.	0.3	154
210	The progress and potential of proteomic biomarkers for type 1 diabetes in children. <i>Expert Review of Proteomics</i> , 2017, 14, 31-41.	1.3	7

#	ARTICLE	IF	CITATIONS
211	Need for Better Diabetes Treatment: The Therapeutic Potential of NMDA Receptor Antagonists. <i>Klinische Padiatrie</i> , 2017, 229, 14-20.	0.2	6
212	Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home. <i>Clinical and Experimental Immunology</i> , 2017, 188, 226-233.	1.1	13
213	Kinin receptors: Key regulators of autoimmunity. <i>Autoimmunity Reviews</i> , 2017, 16, 192-207.	2.5	45
214	2. Classification and Diagnosis of Diabetes. <i>Diabetes Care</i> , 2017, 40, S11-S24.	4.3	1,420
215	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017, 66, 241-255.	0.3	454
216	Management of Type 1 Diabetes. <i>Nursing Clinics of North America</i> , 2017, 52, 499-511.	0.7	15
217	MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis. <i>Endocrine Connections</i> , 2017, 6, 773-790.	0.8	118
218	Activation of CD4+ and CD8+ T-lymphocytes by insulin and GAD in patients with type 1 or 2 diabetes mellitus. <i>Endocrine Connections</i> , 2017, 6, 758-765.	0.8	5
219	Have we pushed the needle for treatment of Type 1 diabetes?. <i>Current Opinion in Immunology</i> , 2017, 49, 44-50.	2.4	7
220	Markers influencing the presence of partial clinical remission in patients with newly diagnosed type 1 diabetes. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2017, 30, 1147-1153.	0.4	21
221	T Cell Receptor Profiling in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2017, 17, 118.	1.7	26
222	Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2017, 17, 119.	1.7	21
223	Evolution of autoantibody responses in individuals at risk of rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 42-52.	1.4	12
224	Joint modeling of longitudinal autoantibody patterns and progression to type 1 diabetes: results from the TEDDY study. <i>Acta Diabetologica</i> , 2017, 54, 1009-1017.	1.2	24
225	The Influence of Type 1 Diabetes Genetic Susceptibility Regions, Age, Sex, and Family History on the Progression From Multiple Autoantibodies to Type 1 Diabetes: A TEDDY Study Report. <i>Diabetes</i> , 2017, 66, 3122-3129.	0.3	93
226	Deciphering the Pathogenesis of Human Type 1 Diabetes (T1D) by Interrogating T Cells from the "Scene of the Crime". <i>Current Diabetes Reports</i> , 2017, 17, 95.	1.7	28
227	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. <i>Diabetes Care</i> , 2017, 40, 1494-1499.	4.3	28
228	Immunological Issues After Stem Cell-Based β Cell Replacement. <i>Current Diabetes Reports</i> , 2017, 17, 68.	1.7	19

#	ARTICLE	IF	CITATIONS
229	Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. <i>Journal of Autoimmunity</i> , 2017, 83, 95-112.	3.0	108
230	Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis. <i>Molecular Metabolism</i> , 2017, 6, 943-957.	3.0	352
231	Building and validating a prediction model for paediatric type 1 diabetes risk using next generation targeted sequencing of class II HLA genes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2921.	1.7	2
233	The Role of Epigenetics in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2017, 17, 89.	1.7	69
234	Flexible Bayesian additive joint models with an application to type 1 diabetes research. <i>Biometrical Journal</i> , 2017, 59, 1144-1165.	0.6	15
236	Genetic and Environmental Interactions Modify the Risk of Diabetes-Related Autoimmunity by 6 Years of Age: The TEDDY Study. <i>Diabetes Care</i> , 2017, 40, 1194-1202.	4.3	138
237	Early prediction of autoimmune (type 1) diabetes. <i>Diabetologia</i> , 2017, 60, 1370-1381.	2.9	136
238	Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and <i>HLA-DQ</i> Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1065-1072.	4.3	43
239	Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2881-2886.	1.8	35
240	Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control. <i>Diabetes Care</i> , 2017, 40, 1249-1255.	4.3	124
241	Reclassification of asymptomatic beta cell autoimmunity: a critical perspective. <i>Diabetologia</i> , 2017, 60, 39-42.	2.9	5
242	Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. <i>Diabetologia</i> , 2017, 60, 35-38.	2.9	28
243	Peptide serum markers in islet autoantibody-positive children. <i>Diabetologia</i> , 2017, 60, 287-295.	2.9	24
244	Type 1 diabetes: a disease of developmental origins. <i>Pediatric Diabetes</i> , 2017, 18, 417-421.	1.2	12
245	Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 99-114.	1.1	10
246	Circulating CXCR5+PD-1+ICOS+ Follicular T Helper Cells Are Increased Close to the Diagnosis of Type 1 Diabetes in Children With Multiple Autoantibodies. <i>Diabetes</i> , 2017, 66, 437-447.	0.3	94
247	Early life origin of type 1 diabetes. <i>Seminars in Immunopathology</i> , 2017, 39, 653-667.	2.8	23
248	Type 1 Diabetes: Disease Stratification. <i>Biomedicine Hub</i> , 2017, 2, 1-16.	0.4	10

#	ARTICLE	IF	CITATIONS
249	The Genetic Architecture of Type 1 Diabetes. <i>Genes</i> , 2017, 8, 209.	1.0	49
250	Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. <i>Frontiers in Endocrinology</i> , 2017, 8, 232.	1.5	44
252	Perceptions of predictive testing for those at risk of developing a chronic inflammatory disease: a meta-synthesis of qualitative studies. <i>Journal of Risk Research</i> , 2018, 21, 167-189.	1.4	12
253	Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1966-1976.	1.8	10
254	Definition, Diagnosis and Classification of Diabetes Mellitus. , 2018, , 7-18.		3
255	Pathogenesis of Type 1 Diabetes. <i>Endocrinology</i> , 2018, , 1-40.	0.1	0
256	Mining the Virome for Insights into Type 1 Diabetes. <i>DNA and Cell Biology</i> , 2018, 37, 422-425.	0.9	10
257	Predicting progression to diabetes in islet autoantibody positive children. <i>Journal of Autoimmunity</i> , 2018, 90, 59-63.	3.0	17
258	Teasing Diabetes Apart, One Locus at a Time. <i>Diabetes Care</i> , 2018, 41, 224-226.	4.3	2
259	A novel LIPS assay for insulin autoantibodies. <i>Acta Diabetologica</i> , 2018, 55, 263-270.	1.2	36
260	Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 38.	3.8	105
261	A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	49
262	Contrast-enhanced ultrasound measurement of pancreatic blood flow dynamics predicts type 1 diabetes progression in preclinical models. <i>Nature Communications</i> , 2018, 9, 1742.	5.8	33
263	Clinical and research uses of genetic risk scores in type 1 diabetes. <i>Current Opinion in Genetics and Development</i> , 2018, 50, 96-102.	1.5	23
264	Presymptomatic screening for autoimmune β -cell disorder: Baby steps toward prevention?. <i>Pediatric Diabetes</i> , 2018, 19, 11-13.	1.2	1
265	First trimester enterovirus IgM and beta cell autoantibodies in mothers to children affected by type 1 diabetes autoimmunity before 7 years of age. <i>Journal of Reproductive Immunology</i> , 2018, 127, 1-6.	0.8	4
266	Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. <i>Diabetologia</i> , 2018, 61, 1484-1490.	2.9	32
267	Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling. <i>Scientific Reports</i> , 2018, 8, 4529.	1.6	59

#	ARTICLE	IF	CITATIONS
268	Aspectos clínicos y diagnósticos de la diabetes infantil. EMC Pediatría, 2018, 53, 1-22.	0.0	0
269	Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes. Diabetes Care, 2018, 41, 653-661.	4.3	55
270	Adverse Events Associated with Immune Checkpoint Blockade. New England Journal of Medicine, 2018, 378, 1163-1165.	13.9	79
271	Accelerated Progression to Type 1 Diabetes in the Presence of <i>HLA-A*24</i> and <i>B*18</i> Is Restricted to Multiple Islet Autoantibody-Positive Individuals With Distinct <i>HLA-DQ</i> and Autoantibody Risk Profiles. Diabetes Care, 2018, 41, 1076-1083.	4.3	16
272	Primary islet autoantibody at initial seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease heterogeneity. Pediatric Diabetes, 2018, 19, 284-292.	1.2	39
273	Pathways governing development of stem cell-derived pancreatic β cells: lessons from embryogenesis. Biological Reviews, 2018, 93, 364-389.	4.7	37
274	Hyperglycemia induced reactive species trigger structural changes in human serum albumin of type 1 diabetic subjects. International Journal of Biological Macromolecules, 2018, 107, 2141-2149.	3.6	7
275	Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. Diabetes, 2018, 67, 146-154.	0.3	72
276	Aetiology of type 1 diabetes: Physiological growth in children affects disease progression. Diabetes, Obesity and Metabolism, 2018, 20, 775-785.	2.2	9
277	Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident β -cell autoantibodies. Journal of Autoimmunity, 2018, 86, 93-103.	3.0	22
278	Pandemic Influenza A H1N1 Vaccination and Subsequent Risk of Type 1 Diabetes in Norway. Epidemiology, 2018, 29, e6-e8.	1.2	4
279	Risk of beta-cell autoimmunity presence for progression to type 1 diabetes: A systematic review and meta-analysis. Journal of Autoimmunity, 2018, 86, 9-18.	3.0	9
280	Temporal expression profiling of plasma proteins reveals oxidative stress in early stages of Type 1 Diabetes progression. Journal of Proteomics, 2018, 172, 100-110.	1.2	36
281	The chromosome 6q22.33 region is associated with age at diagnosis of type 1 diabetes and disease risk in those diagnosed under 5 years of age. Diabetologia, 2018, 61, 147-157.	2.9	37
282	Proteomic Landscape of Patient-Derived CD4+ T Cells in Recent-Onset Type 1 Diabetes. Journal of Proteome Research, 2018, 17, 618-634.	1.8	33
283	Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatric Diabetes, 2018, 19, 271-276.	1.2	0
284	Understanding childhood diabetes mellitus: new pathophysiological aspects. Journal of Inherited Metabolic Disease, 2018, 41, 19-27.	1.7	10
285	A subclass of serum anti-ZnT8 antibodies directed to the surface of live pancreatic β -cells. Journal of Biological Chemistry, 2018, 293, 579-587.	1.6	16

#	ARTICLE	IF	CITATIONS
286	Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. <i>Pediatric Diabetes</i> , 2018, 19, 410-419.	1.2	45
287	Screening, staging, and naming of presymptomatic type 1 diabetes. <i>Pediatric Diabetes</i> , 2018, 19, 7-10.	1.2	9
288	2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetesâ€™2018</i>. <i>Diabetes Care</i> , 2018, 41, S13-S27.	4.3	2,534
289	Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children. <i>Diabetologia</i> , 2018, 61, 193-202.	2.9	18
290	Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction. <i>Islets</i> , 2018, 10, 10-24.	0.9	23
291	25-Hydroxyvitamin D, Autoantigenic and Total Antibody Concentrations: Results from a Danish Case-control Study of Newly Diagnosed Patients with Childhood Type 1 Diabetes and their Healthy Siblings™. <i>Scandinavian Journal of Immunology</i> , 2018, 87, 46-53.	1.3	5
292	Characterization of the Human Pancreas Side Population as a Potential Reservoir of Adult Stem Cells. <i>Pancreas</i> , 2018, 47, 25-34.	0.5	5
294	Mycobacteria, Immunoregulation, and Autoimmunity. , 2018, , 121-154.		1
296	The Dynamic Origins of Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2441-2443.	4.3	4
297	Type 1 Diabetes Recurrence After Simultaneous Pancreas-Kidney Transplantation. <i>Current Transplantation Reports</i> , 2018, 5, 295-303.	0.9	0
298	Pancreas Pathology During the Natural History of Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2018, 18, 124.	1.7	39
299	Association between maternal gluten intake and type 1 diabetes in offspring: national prospective cohort study in Denmark. <i>BMJ: British Medical Journal</i> , 2018, 362, k3547.	2.4	41
301	Proinsulin C-peptide is an autoantigen in people with type 1 diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10732-10737.	3.3	47
303	High prevalence of humoral autoimmunity in first-degree relatives of Mexican type 1 diabetes patients. <i>Acta Diabetologica</i> , 2018, 55, 1275-1282.	1.2	2
304	The Development of Immunotherapy Strategies for the Treatment of Type 1 Diabetes. <i>Frontiers in Medicine</i> , 2018, 5, 283.	1.2	14
305	Dietary Cows™ Milk Protein A1 Beta-Casein Increases the Incidence of T1D in NOD Mice. <i>Nutrients</i> , 2018, 10, 1291.	1.7	30
306	Recruiting young pre-symptomatic children for a clinical trial in type 1 diabetes: Insights from the Fr1da insulin intervention study. <i>Contemporary Clinical Trials Communications</i> , 2018, 11, 170-173.	0.5	9
307	ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2018, 19, 7-19.	1.2	424

#	ARTICLE	IF	CITATIONS
308	Immunological biomarkers for the development and progression of type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 2252-2258.	2.9	51
309	Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes. <i>Frontiers in Immunology</i> , 2018, 9, 1891.	2.2	24
310	The Intricate Relationship between Diabetes, Diet and the Gut Microbiota. , 2018, , .		0
311	Maternal infection during pregnancy and type 1 diabetes mellitus in offspring: a systematic review and meta-analysis. <i>Epidemiology and Infection</i> , 2018, 146, 2131-2138.	1.0	15
312	Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 2356-2370.	2.9	33
313	Immune Mechanisms and Pathways Targeted in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2018, 18, 90.	1.7	29
314	Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetesâ€”The TrialNet Experience. <i>Diabetes</i> , 2018, 67, 1216-1225.	0.3	29
316	Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or Tj ETQq1 1 0.784314 rgBT /Overl 67, 1197-1208.	2.0	24
317	MicroRNAs: markers of β -cell stress and autoimmunity. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 237-245.	1.2	19
318	Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children. <i>PLoS Medicine</i> , 2018, 15, e1002548.	3.9	101
319	Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk. <i>Diabetologia</i> , 2018, 61, 2043-2053.	2.9	26
321	Anti-Insulin B Cells Are Poised for Antigen Presentation in Type 1 Diabetes. <i>Journal of Immunology</i> , 2018, 201, 861-873.	0.4	23
322	Pandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort study. <i>Diabetologia</i> , 2018, 61, 1996-2004.	2.9	39
323	Learning From Past Failures of Oral Insulin Trials. <i>Diabetes</i> , 2018, 67, 1211-1215.	0.3	11
324	ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2018, 19, 20-27.	1.2	89
325	Understanding Pre-Type 1 Diabetes: The Key to Prevention. <i>Frontiers in Endocrinology</i> , 2018, 9, 70.	1.5	25
326	Type 1 Diabetes and Its Multi-Factorial Pathogenesis: The Putative Role of NK Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 794.	1.8	32
327	Dynamics of Plasma Lipidome in Progression to Islet Autoimmunity and Type 1 Diabetes â€” Type 1 Diabetes Prediction and Prevention Study (DIPP). <i>Scientific Reports</i> , 2018, 8, 10635.	1.6	56

#	ARTICLE	IF	CITATIONS
328	Ethylencarbodiimide-fixed splenocytes carrying whole islet antigens decrease the incidence of diabetes in NOD mice <i>via</i> down-regulation of effector memory T cells and autoantibodies. <i>Endocrine Journal</i> , 2018, 65, 943-952.	0.7	2
329	Effector T Cell Resistance to Suppression and STAT3 Signaling during the Development of Human Type 1 Diabetes. <i>Journal of Immunology</i> , 2018, 201, 1144-1153.	0.4	21
330	Live attenuated enterovirus vaccine (OPV) is not associated with islet autoimmunity in children with genetic susceptibility to type 1 diabetes: prospective cohort study. <i>Diabetologia</i> , 2018, 61, 203-209.	2.9	5
331	Reduction in White Blood Cell, Neutrophil, and Red Blood Cell Counts Related to Sex, HLA, and Islet Autoantibodies in Swedish TEDDY Children at Increased Risk for Type 1 Diabetes. <i>Diabetes</i> , 2018, 67, 2329-2336.	0.3	15
332	Serum biomarkers for diagnosis and prediction of type 1 diabetes. <i>Translational Research</i> , 2018, 201, 13-25.	2.2	42
333	Challenges to Reshape the Future of Type 1 Diabetes Research. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2838-2842.	1.8	5
334	Healthy Donor Polyclonal IgMs Diminish B-Lymphocyte Autoreactivity, Enhance Regulatory T-Cell Generation, and Reverse Type 1 Diabetes in NOD Mice. <i>Diabetes</i> , 2018, 67, 2349-2360.	0.3	6
335	Prevention of Type 1 Diabetes. <i>Endocrinology</i> , 2018, , 1-13.	0.1	2
336	Class II HLA Genotype Association With First-Phase Insulin Response Is Explained by Islet Autoantibodies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2870-2878.	1.8	7
337	Regulation of T Follicular Helper Cells in Islet Autoimmunity. <i>Frontiers in Immunology</i> , 2018, 9, 1729.	2.2	8
338	Type 1 diabetes. <i>Lancet, The</i> , 2018, 391, 2449-2462.	6.3	888
339	Diabetes associated with immune checkpoint inhibition: presentation and management challenges. <i>Diabetic Medicine</i> , 2018, 35, 1283-1290.	1.2	25
340	Common ground: shared risk factors for type 1 diabetes and celiac disease. <i>Nature Immunology</i> , 2018, 19, 685-695.	7.0	33
341	Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 192-199.	4.3	27
342	Islet Microvasculature Alterations With Loss of Beta-cells in Patients With Type 1 Diabetes. <i>Journal of Histochemistry and Cytochemistry</i> , 2019, 67, 41-52.	1.3	31
343	Type 1 Diabetes. , 2019, , 957-966.e1.		5
344	Harnessing CXCL12 signaling to protect and preserve functional β -cell mass and for cell replacement in type 1 diabetes. , 2019, 193, 63-74.		18
345	Screening children for type 1 diabetes-associated antibodies at community health fairs. <i>Pediatric Diabetes</i> , 2019, 20, 909-914.	1.2	5

#	ARTICLE	IF	CITATIONS
346	Prediction and prevention of type 1 diabetes in children. <i>Clinical Pediatric Endocrinology</i> , 2019, 28, 43-57.	0.4	9
347	Birth and coming of age of islet autoantibodies. <i>Clinical and Experimental Immunology</i> , 2019, 198, 294-305.	1.1	35
348	Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3857.	1.8	9
349	Extracellular Vesicles in Type 1 Diabetes: Messengers and Regulators. <i>Current Diabetes Reports</i> , 2019, 19, 69.	1.7	16
350	Controversies in medicine: redefining the diagnosis of type 1 diabetes. <i>Medical Journal of Australia</i> , 2019, 211, 157.	0.8	5
351	Landmark models to define the age-adjusted risk of developing stage 1 type 1 diabetes across childhood and adolescence. <i>BMC Medicine</i> , 2019, 17, 125.	2.3	10
352	Age, HLA, and Sex Define a Marked Risk of Organ-Specific Autoimmunity in First-Degree Relatives of Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1684-1691.	4.3	12
353	Characteristics of Slow Progression to Type 1 Diabetes in Children With Increased HLA-Conferred Disease Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5585-5594.	1.8	11
354	Early Detection of Peripheral Blood Cell Signature in Children Developing β^2 -Cell Autoimmunity at a Young Age. <i>Diabetes</i> , 2019, 68, 2024-2034.	0.3	37
355	Autoimmune Polyendocrinopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4769-4782.	1.8	48
356	Diabetes in Children and Adolescents. , 2019, , 941-966.		0
357	Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. <i>BMJ Open</i> , 2019, 9, e028578.	0.8	62
358	Circulating CXCR5 ^{hi} PD-1 ^{hi} peripheral T helper cells are associated with progression to type 1 diabetes. <i>Diabetologia</i> , 2019, 62, 1681-1688.	2.9	57
359	Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials ^{â€”} GPPAD ^{â€”} 02 study design and first results. <i>Pediatric Diabetes</i> , 2019, 20, 720-727.	1.2	31
360	Metabolite-related dietary patterns and the development of islet autoimmunity. <i>Scientific Reports</i> , 2019, 9, 14819.	1.6	34
362	Type 1 Diabetes Mellitus (Juvenile Diabetes) ^{â€”} A Review for the Pediatric Oral Health Provider. <i>Journal of Clinical Pediatric Dentistry</i> , 2019, 43, 417-423.	0.5	10
363	Shared and unique immune alterations in pre-clinical autoimmunity. <i>Current Opinion in Immunology</i> , 2019, 61, 60-68.	2.4	8
364	High-throughput multiplexed autoantibody detection to screen type 1 diabetes and multiple autoimmune diseases simultaneously. <i>EBioMedicine</i> , 2019, 47, 365-372.	2.7	23

#	ARTICLE	IF	CITATIONS
365	Imagining a better future for all people with type 1 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2019, 15, 623-624.	4.3	5
366	What has zinc transporter 8 autoimmunity taught us about type 1 diabetes?. <i>Diabetologia</i> , 2019, 62, 1969-1976.	2.9	23
367	Circulating metabolites in progression to islet autoimmunity and type 1 diabetes. <i>Diabetologia</i> , 2019, 62, 2287-2297.	2.9	30
368	Age at Seroconversion, HLA Genotype, and Specificity of Autoantibodies in Progression of Islet Autoimmunity in Childhood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4521-4530.	1.8	23
369	Could hyperglycemia-induced cardiac autoimmunity be hidden behind cardiovascular disease in type 1 diabetes mellitus?. <i>Metabolism Open</i> , 2019, 3, 100013.	1.4	1
370	What Have Slow Progressors Taught Us About T1D? Mind the Gap!. <i>Current Diabetes Reports</i> , 2019, 19, 99.	1.7	3
371	Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance. <i>Biochemistry</i> , 2019, 58, 4107-4111.	1.2	30
372	The heterogeneous pathogenesis of type 1 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2019, 15, 635-650.	4.3	249
373	The role of T cell miRNAs for regulatory T cell induction in islet autoimmunity. <i>Molecular Metabolism</i> , 2019, 27, S122-S128.	3.0	12
374	Evaluation of cellular and humoral autoimmunity before the development of type 1 diabetes in a patient with idiopathic CD 4 lymphocytopenia. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1108-1111.	1.1	2
375	Antibodies to oxidized insulin improve prediction of type 1 diabetes in children with positive standard islet autoantibodies. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3132.	1.7	16
376	Genetic Contribution to the Divergence in Type 1 Diabetes Risk Between Children From the General Population and Children From Affected Families. <i>Diabetes</i> , 2019, 68, 847-857.	0.3	22
377	Probing the Meaning of Persistent Propeptide Release in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 183-185.	4.3	5
378	Regulation of Diabetogenic Immunity by IL-15-Activated Regulatory CD8 T Cells in Type 1 Diabetes. <i>Journal of Immunology</i> , 2019, 203, 158-166.	0.4	11
379	Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes. <i>FEBS Letters</i> , 2019, 593, 1598-1615.	1.3	85
380	Detecting autoreactive B cells in the peripheral blood of people with type 1 diabetes using ELISpot. <i>Journal of Immunological Methods</i> , 2019, 471, 61-65.	0.6	6
381	Metabolomics of Type 1 and Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2467.	1.8	151
382	Perinatal risk factors for type 1 diabetes revisited: a population-based register study. <i>Diabetologia</i> , 2019, 62, 1173-1184.	2.9	42

#	ARTICLE	IF	CITATIONS
383	Study of the difficult glycemic control in relation to the presence of diabetes-autoantibodies in a sample of Egyptians with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 152, 53-57.	1.1	0
384	Serum 25-Hydroxyvitamin D Concentrations at Birth in Children Screened for HLA-DQB1 Conferred Risk for Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2277-2285.	1.8	12
385	The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 879-886.	0.3	42
386	Diagnosis, Therapy and Follow-up of Diabetes Mellitus in Children and Adolescents. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 341-352.	0.6	12
387	Analysis of diabetes-associated autoantibodies in children and adolescents with autoimmune thyroid diseases. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2019, 32, 355-361.	0.4	4
388	Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes. <i>Frontiers in Immunology</i> , 2019, 10, 365.	2.2	9
389	Pancreatic autoantibodies and CD14+CD16+ monocytes subset are associated with the impairment of β -cell function after simultaneous pancreas-kidney transplantation. <i>PLoS ONE</i> , 2019, 14, e0212547.	1.1	1
391	Feasibility and organization of a population-based screening for pre-symptomatic type 1 diabetes in children – evaluation of the Fr1da study. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2019, 27, 553-560.	0.8	3
393	Prevalence of diabetes and presence of autoantibodies against zinc transporter 8 and glutamic decarboxylase at diagnosis and at follow up of Graves' disease. <i>Endocrine</i> , 2019, 64, 48-54.	1.1	9
394	Gluten Intake and Risk of Islet Autoimmunity and Progression to Type 1 Diabetes in Children at Increased Risk of the Disease: The Diabetes Autoimmunity Study in the Young (DAISY). <i>Diabetes Care</i> , 2019, 42, 789-796.	4.3	31
395	Screening for asymptomatic β -cell autoimmunity in young children. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 288-290.	2.7	8
396	FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children. <i>Frontiers in Immunology</i> , 2019, 10, 19.	2.2	40
398	2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes – 2019. <i>Diabetes Care</i> , 2019, 42, S13-S28.	4.3	2,164
399	The Immunoreactive Platform of the Pancreatic Islets Influences the Development of Autoreactivity. <i>Diabetes</i> , 2019, 68, 1544-1551.	0.3	13
400	Rationally designed small molecules to prevent type 1 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 90-95.	1.2	5
401	A Systematic Review of Childhood Diabetes Research in the Middle East Region. <i>Frontiers in Endocrinology</i> , 2019, 10, 805.	1.5	21
402	The gut microbiota in type 1 diabetes: friend or foe?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 207-212.	1.2	34
403	Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 195-200.	1.2	16

#	ARTICLE	IF	CITATIONS
404	miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. <i>Nature Communications</i> , 2019, 10, 5697.	5.8	48
405	Development of a Simple Multiplex Electrochemiluminescence (ECL) Assay for Screening Pre-Type 1 Diabetes and Multiple Relevant Autoimmune Diseases. , 2019, , .		0
406	Immunomodulatory Effect of Vitamin D and Its Potential Role in the Prevention and Treatment of Type 1 Diabetes Mellitusâ€”A Narrative Review. <i>Molecules</i> , 2019, 24, 53.	1.7	58
407	Neopeptides: a new take on beta cell autoimmunity in type 1 diabetes. <i>Diabetologia</i> , 2019, 62, 351-356.	2.9	20
408	Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children. <i>Pediatric Diabetes</i> , 2019, 20, 263-270.	1.2	31
409	Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice. <i>Drugs</i> , 2019, 79, 43-61.	4.9	37
410	Development and Standardization of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn Screening and Incident Diagnosis. <i>Diabetes Care</i> , 2019, 42, 200-207.	4.3	187
411	Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children. <i>Diabetes</i> , 2019, 68, 119-130.	0.3	28
412	A stochastic epigenetic Mendelian oligogenic disease model for type 1 diabetes. <i>Journal of Autoimmunity</i> , 2019, 96, 123-133.	3.0	4
413	Progression from islet autoimmunity to clinical type 1 diabetes is influenced by genetic factors: results from the prospective TEDDY study. <i>Journal of Medical Genetics</i> , 2019, 56, 602-605.	1.5	22
414	Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders. <i>Schizophrenia Bulletin</i> , 2019, 45, 233-246.	2.3	28
415	Autoantibodies and HLA class II DR-DQ genotypes in Ugandan children and adolescents with type 1 diabetes mellitus. <i>International Journal of Diabetes in Developing Countries</i> , 2019, 39, 39-46.	0.3	5
416	Harmonization of immunoassays for biomarkers in diabetes mellitus. <i>Biotechnology Advances</i> , 2020, 39, 107359.	6.0	34
417	On the dynamics of the human endocrine pancreas and potential consequences for the development of type 1 diabetes. <i>Acta Diabetologica</i> , 2020, 57, 503-511.	1.2	9
418	Prevention of Autoimmune Disease: The Type 1 Diabetes Paradigm. , 2020, , 1391-1413.		0
419	Islet autoantibodies in disease prediction and pathogenesis. <i>Diabetology International</i> , 2020, 11, 6-10.	0.7	12
420	Autoimmune (Type 1) Diabetes. , 2020, , 769-787.		4
421	Hyaluronan deposition in islets may precede and direct the location of islet immune-cell infiltrates. <i>Diabetologia</i> , 2020, 63, 549-560.	2.9	9

#	ARTICLE	IF	CITATIONS
422	Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 351-361.	2.9	22
423	The changing face of paediatric diabetes. <i>Diabetologia</i> , 2020, 63, 683-691.	2.9	23
424	From immunohistological to anatomical alterations of human pancreas in type 1 diabetes: New concepts on the stage. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3264.	1.7	20
425	Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis. <i>Diabetes</i> , 2020, 69, 413-423.	0.3	29
426	New Frontiers in the Treatment of Type 1 Diabetes. <i>Cell Metabolism</i> , 2020, 31, 46-61.	7.2	147
427	Allostasis and the origins of adult-onset diabetes. <i>Diabetologia</i> , 2020, 63, 261-265.	2.9	6
428	The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. <i>Diabetologia</i> , 2020, 63, 588-596.	2.9	58
429	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 5-12.	4.3	220
430	Reduced PD-1 expression on circulating follicular and conventional FOXP3+ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children. <i>Clinical Immunology</i> , 2020, 211, 108319.	1.4	16
431	Recurrence of type 1 diabetes following simultaneous pancreas-kidney transplantation. , 2020, , 295-311.		0
432	Predicting the function of islets after transplantation. , 2020, , 547-561.		2
433	Identification of a subgroup of black South Africans with type 1 diabetes who are older at diagnosis but have lower levels of glutamic acid decarboxylase and islet antigen 2 autoantibodies. <i>Diabetic Medicine</i> , 2020, 37, 2067-2074.	1.2	9
434	Type 1 diabetes can present before the age of 6 months and is characterised by autoimmunity and rapid loss of beta cells. <i>Diabetologia</i> , 2020, 63, 2605-2615.	2.9	24
435	Characterization of plasma lipidomics in adolescent subjects with increased risk for type 1 diabetes in the DiPiS cohort. <i>Metabolomics</i> , 2020, 16, 109.	1.4	1
436	Extended family history of type 1 diabetes in <sc>HLA</sc> -predisposed children with and without islet autoantibodies. <i>Pediatric Diabetes</i> , 2020, 21, 1447-1456.	1.2	4
438	Metabolic Signatures of the Exposome – Quantifying the Impact of Exposure to Environmental Chemicals on Human Health. <i>Metabolites</i> , 2020, 10, 454.	1.3	25
439	Emerging Roles of Exosomes in T1DM. <i>Frontiers in Immunology</i> , 2020, 11, 593348.	2.2	44
440	miRNA-Mediated Immune Regulation in Islet Autoimmunity and Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2020, 11, 606322.	1.5	15

#	ARTICLE	IF	CITATIONS
441	A combined risk score enhances prediction of type 1 diabetes among susceptible children. <i>Nature Medicine</i> , 2020, 26, 1247-1255.	15.2	83
442	B cell helper T cells and type 1 diabetes. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12943.	1.3	14
443	miRNA Regulation of T Cells in Islet Autoimmunity and Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2020, 20, 41.	1.7	14
444	Sphingolipids in Type 1 Diabetes: Focus on Beta-Cells. <i>Cells</i> , 2020, 9, 1835.	1.8	11
445	2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020. <i>Diabetes Care</i> , 2020, 43, S14-S31.	4.3	2,192
446	Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	78
447	Mucosal-associated invariant T cell alterations during the development of human type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 2396-2409.	2.9	13
448	Circulating TFH cells as a marker for early therapeutic intervention in T1D. <i>Nature Immunology</i> , 2020, 21, 1141-1142.	7.0	3
449	Dynamics of Islet Autoantibodies During Prospective Follow-Up From Birth to Age 15 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4638-e4651.	1.8	35
450	Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities. <i>Journal of Clinical Medicine</i> , 2020, 9, 2805.	1.0	11
452	Novel genetic risk factors influence progression of islet autoimmunity to type 1 diabetes. <i>Scientific Reports</i> , 2020, 10, 19193.	1.6	5
453	Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside. <i>Biomolecules</i> , 2020, 10, 1681.	1.8	17
454	Snorting the Brain Away: Cerebral Damage as an Extension of Cocaine-Induced Midline Destructive Lesions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1365-1369.	0.9	4
455	A Question of Tolerance—Antigen-Specific Immunotherapy for Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2020, 20, 70.	1.7	7
456	Pediatric Type 2 Diabetes: Not a Mini Version of Adult Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 679-693.	1.2	12
457	Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado. <i>Diabetes Care</i> , 2020, 43, 1496-1503.	4.3	53
458	Gluten-free diet impact on dynamics of pancreatic islet-specific autoimmunity detected at celiac disease diagnosis. <i>Pediatric Diabetes</i> , 2020, 21, 774-780.	1.2	4
459	A plasmonic nanoledge array sensor for detection of anti-insulin antibodies of type 1 diabetes biomarker. <i>Nanotechnology</i> , 2020, 31, 325503.	1.3	3

#	ARTICLE	IF	CITATIONS
461	Type 1 diabetes, thyroid, gastric and adrenal humoral autoantibodies are present altogether in almost one third of adult celiac patients at diagnosis, with a higher frequency than children and adolescent celiac patients. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 549-554.	0.6	7
462	Decreased HLA-DQ expression on peripheral blood cells in children with varying number of beta cell autoantibodies. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100052.	2.0	5
463	Microbiota derived factors as drivers of type 1 diabetes. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 171, 215-235.	0.9	2
464	Risk of Islet and Celiac Autoimmunity in Cotwins of Proband With Type 1 Diabetes. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa053.	0.1	0
465	Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020, 63, 1671-1693.	2.9	102
466	Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 1617-1635.	4.3	204
467	Prediction and Prevention of Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2020, 11, 248.	1.5	41
468	Zonulin as a potential putative biomarker of risk for shared type 1 diabetes and celiac disease autoimmunity. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3309.	1.7	34
469	Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype. <i>Diabetologia</i> , 2020, 63, 1174-1185.	2.9	18
470	The MHC-II peptidome of pancreatic islets identifies key features of autoimmune peptides. <i>Nature Immunology</i> , 2020, 21, 455-463.	7.0	53
471	Fungal Dysbiosis and Intestinal Inflammation in Children With Beta-Cell Autoimmunity. <i>Frontiers in Immunology</i> , 2020, 11, 468.	2.2	33
472	Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2103.	1.8	15
473	Microencapsulated G3C Hybridoma Cell Graft Delays the Onset of Spontaneous Diabetes in NOD Mice by an Expansion of Citr+ Treg Cells. <i>Diabetes</i> , 2020, 69, 965-980.	0.3	7
474	Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study. <i>Diabetes Care</i> , 2020, 43, 2066-2073.	4.3	41
475	Type 1 diabetes's early life origins and changing epidemiology. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 226-238.	5.5	187
476	Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes. <i>Medicinal Research Reviews</i> , 2020, 40, 1200-1219.	5.0	27
477	Metabolic alterations in immune cells associate with progression to type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 1017-1031.	2.9	42
478	Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 339.	3.8	139

#	ARTICLE	IF	CITATIONS
479	Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 333-358.	0.9	14
480	The serum concentration of β^2 CGRP is novel marker for type 1 diabetes. <i>Heliyon</i> , 2020, 6, e03223.	1.4	1
481	Parental anxiety after 5 years of participation in a longitudinal study of children at high risk of type 1 diabetes. <i>Pediatric Diabetes</i> , 2020, 21, 878-889.	1.2	5
482	Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. <i>Diabetes Care</i> , 2020, 43, 580-587.	4.3	41
483	Antipyretics might occupy a narrow temporal position in aetiology of type 1 diabetes: Immunological and intestinal studies required. <i>Medical Hypotheses</i> , 2020, 141, 109708.	0.8	0
484	Different interaction of onset age and duration of type 1 diabetes on the dynamics of autoantibodies to insulinoma-associated antigen 2 and zinc transporter 8. <i>Journal of Diabetes Investigation</i> , 2021, 12, 510-515.	1.1	6
485	Microencapsulation of cells and molecular therapy of type 1 diabetes mellitus: The actual state and future perspectives between promise and progress. <i>Journal of Diabetes Investigation</i> , 2021, 12, 301-309.	1.1	16
486	The crucial role of early-life gut microbiota in the development of type 1 diabetes. <i>Acta Diabetologica</i> , 2021, 58, 249-265.	1.2	15
487	Immune checkpoint inhibitors and diabetes: Mechanisms and predictors. <i>Diabetes and Metabolism</i> , 2021, 47, 101193.	1.4	9
488	A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. <i>Med</i> , 2021, 2, 149-163.e4.	2.2	85
489	Image-Based Machine Learning Algorithms for Disease Characterization in the Human Type 1 Diabetes Pancreas. <i>American Journal of Pathology</i> , 2021, 191, 454-462.	1.9	19
490	2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2021. <i>Diabetes Care</i> , 2021, 44, S15-S33.	4.3	1,794
491	Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study. <i>Pediatric Diabetes</i> , 2021, 22, 360-368.	1.2	8
492	Pediatric Screenings: Helpful or Hinderance?. <i>Journal for Nurse Practitioners</i> , 2021, 17, 236-240.	0.4	0
493	Plasma Metabolome and Circulating Vitamins Stratified Onset Age of an Initial Islet Autoantibody and Progression to Type 1 Diabetes: The TEDDY Study. <i>Diabetes</i> , 2021, 70, 282-292.	0.3	13
494	Parent and Pediatrician Preferences for Type 1 Diabetes Screening in the U.S.. <i>Diabetes Care</i> , 2021, 44, 332-339.	4.3	5
495	Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00198.	1.0	3
496	Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren. <i>Clinical and Experimental Immunology</i> , 2021, 203, 41-46.	1.1	0

#	ARTICLE	IF	CITATIONS
497	Proinsulin-specific T cell responses correlate with estimated C-peptide and predict partial remission duration in type 1 diabetes. <i>Clinical and Translational Immunology</i> , 2021, 10, e1315.	1.7	15
498	Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. <i>Diabetologia</i> , 2021, 64, 1079-1092.	2.9	31
499	Peripheral autoreactive CD8 T cell frequencies are too variable to be a reliable predictor of disease progression of human type 1 diabetes. <i>Clinical and Translational Immunology</i> , 2021, 10, e1309.	1.7	5
500	B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes. <i>Biomedicine</i> , 2021, 9, 42.	1.4	6
501	Pathophysiology of Types of Pediatric and Adolescent Diabetes. <i>Contemporary Endocrinology</i> , 2021, , 13-24.	0.3	0
502	<i>lgrpr</i> : an interpretable non-parametric method for inferring covariate effects from longitudinal data. <i>Bioinformatics</i> , 2021, 37, 1860-1867.	1.8	6
505	The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetes. <i>Immunology and Cell Biology</i> , 2021, 99, 475-485.	1.0	6
506	Insulinitis in the pancreas of non-diabetic organ donors under age 25 years with multiple circulating autoantibodies against islet cell antigens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 295-304.	1.4	7
507	Identifying the "Achilles heel" of type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2021, 204, 167-178.	1.1	3
508	Harnessing CD8 + T cell exhaustion to treat type 1 diabetes. <i>Immunology and Cell Biology</i> , 2021, 99, 486-495.	1.0	5
509	Associations between diet, the gut microbiome and short chain fatty acids in youth with islet autoimmunity and type 1 diabetes. <i>Pediatric Diabetes</i> , 2021, 22, 425-433.	1.2	5
510	An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood. <i>Diabetes Care</i> , 2021, 44, 2260-2268.	4.3	23
511	Evolving Antibody Therapies for the Treatment of Type 1 Diabetes. <i>Frontiers in Immunology</i> , 2020, 11, 624568.	2.2	11
512	Transforming Growth Factor- β 21 and Receptor for Advanced Glycation End Products Gene Expression and Protein Levels in Adolescents with Type 1 Diabetes Mellitus. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2021, 13, 61-71.	0.4	3
513	Insulin's other life: an autoantigen in type 1 diabetes. <i>Immunology and Cell Biology</i> , 2021, 99, 448-460.	1.0	3
514	T-cell responses to hybrid insulin peptides prior to type 1 diabetes development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
515	Pancreatic islet reserve in type 1 diabetes. <i>Annals of the New York Academy of Sciences</i> , 2021, 1495, 40-54.	1.8	10
516	Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 565-573.	1.1	14

#	ARTICLE	IF	CITATIONS
517	Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice. <i>Frontiers in Immunology</i> , 2021, 12, 645817.	2.2	2
518	Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	142
519	Evidence of genetic epistasis in autoimmune diabetes susceptibility revealed by mouse congenic sublines. <i>Immunogenetics</i> , 2021, 73, 307-319.	1.2	1
520	Diabetes type 1: Can it be treated as an autoimmune disorder?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 859-876.	2.6	8
521	Insulin Receptor-Expressing T Cells Appear in Individuals at Risk for Type 1 Diabetes and Can Move into the Pancreas in C57BL/6 Transgenic Mice. <i>Journal of Immunology</i> , 2021, 206, 1443-1453.	0.4	2
522	Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	22
524	Nine residues in HLA-DQ molecules determine with susceptibility and resistance to type 1 diabetes among young children in Sweden. <i>Scientific Reports</i> , 2021, 11, 8821.	1.6	6
525	Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. <i>Journal of Translational Medicine</i> , 2021, 19, 137.	1.8	41
526	Stress Hyperglycemia in Children and Adolescents as a Prognostic Indicator for the Development of Type 1 Diabetes Mellitus. <i>Frontiers in Pediatrics</i> , 2021, 9, 670976.	0.9	3
527	Type 1 diabetes mellitus: much progress, many opportunities. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	57
528	Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count. <i>Endocrine Reviews</i> , 2021, 42, 584-604.	8.9	31
529	Neoepitopes in Type 1 Diabetes: Etiological Insights, Biomarkers and Therapeutic Targets. <i>Frontiers in Immunology</i> , 2021, 12, 667989.	2.2	26
530	Phospholipid Levels at Seroconversion Are Associated With Resolution of Persistent Islet Autoimmunity: The Diabetes Autoimmunity Study in the Young. <i>Diabetes</i> , 2021, 70, 1592-1601.	0.3	5
531	Emerging Roles of Gut Virome in Pediatric Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4127.	1.8	20
533	Islet autoantibody <sc>types mark</sc> differential clinical characteristics at diagnosis of pediatric type 1 diabetes. <i>Pediatric Diabetes</i> , 2021, 22, 882-888.	1.2	3
534	Land Cover of Early-Life Environment Modulates the Risk of Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1506-1514.	4.3	16
535	Complete blood counts with red blood cell determinants associate with reduced beta-cell function in seroconverted Swedish TEDDY children. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00251.	1.0	3
536	HLA class I hyper-expression unmarks beta cells but not alpha cells to the immune system in pre-diabetes. <i>Journal of Autoimmunity</i> , 2021, 119, 102628.	3.0	14

#	ARTICLE	IF	CITATIONS
537	Early Impairment of Insulin Sensitivity, β -Cell Responsiveness, and Insulin Clearance in Youth with Stage 1 Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2660-2669.	1.8	8
538	HLA class I genes modulate disease risk and age at onset together with DR-DQ in Chinese patients with insulin-requiring type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 2026-2036.	2.9	8
539	The β Cell in Diabetes: Integrating Biomarkers With Functional Measures. <i>Endocrine Reviews</i> , 2021, 42, 528-583.	8.9	21
540	Etiology of Autoimmune Islet Disease: Timing Is Everything. <i>Diabetes</i> , 2021, 70, 1431-1439.	0.3	9
541	Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children. <i>Frontiers in Immunology</i> , 2021, 12, 642166.	2.2	15
542	Islet Autoimmunity and HLA Markers of Presymptomatic and Clinical Type 1 Diabetes: Joint Analyses of Prospective Cohort Studies in Finland, Germany, Sweden, and the U.S.. <i>Diabetes Care</i> , 2021, 44, 2269-2276.	4.3	27
543	Insulin immunotherapy for pretype 1 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 390-396.	1.2	5
544	Immunological predictors of type 1 diabetes mellitus (literature review). <i>Diabetes Mellitus</i> , 2021, 24, 167-174.	0.5	0
545	Noncontiguous T cell epitopes in autoimmune diabetes: From mice to men and back again. <i>Journal of Biological Chemistry</i> , 2021, 297, 100827.	1.6	8
546	Preventing type 1 diabetes in childhood. <i>Science</i> , 2021, 373, 506-510.	6.0	52
547	Prevention of type 1 diabetes: where we are and where we are going. <i>Minerva Pediatrics</i> , 2022, 73, .	0.2	1
548	Altered islet prohormone processing: a cause or consequence of diabetes?. <i>Physiological Reviews</i> , 2022, 102, 155-208.	13.1	15
549	100 years of insulin: celebrating the past, present and future of diabetes therapy. <i>Nature Medicine</i> , 2021, 27, 1154-1164.	15.2	94
550	Viruses and Type 1 Diabetes: From Enteroviruses to the Virome. <i>Microorganisms</i> , 2021, 9, 1519.	1.6	23
551	The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7493.	1.8	11
552	The dark side of insulin: A primary autoantigen and instrument of self-destruction in type 1 diabetes. <i>Molecular Metabolism</i> , 2021, 52, 101288.	3.0	9
553	Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?. <i>ImmunoHorizons</i> , 2021, 5, 535-542.	0.8	5
554	Neutrophils and their role in the aetiopathogenesis of type 1 and type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3483.	1.7	12

#	ARTICLE	IF	CITATIONS
556	Ten years follow up of first degree relatives of type 1 diabetes patients: presence of autoimmune biomarkers and the progression to diabetes in a retrospective cohort. Archives of Endocrinology and Metabolism, 2021, 65, 436-442.	0.3	0
557	Immunogenetic Epidemiology of Type 1 Diabetes in 14 Continental Western European Countries. Journal of Immunological Sciences, 2021, 5, 29-35.	0.5	4
558	Novel autoantibodies to the Î²-cell surface epitopes of ZnT8 in patients progressing to type-1 diabetes. Journal of Autoimmunity, 2021, 122, 102677.	3.0	11
559	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia, 2021, 64, 2432-2444.	2.9	8
560	Overcoming Obstacles in the Development of Antigen-Specific Immunotherapies for Type 1 Diabetes. Frontiers in Immunology, 2021, 12, 730414.	2.2	4
562	Zinc transporter 8 autoantibody testing requires age-related cut-offs. BMJ Open Diabetes Research and Care, 2021, 9, e002296.	1.2	4
563	The Kynurenine Pathwayâ€™New Linkage between Innate and Adaptive Immunity in Autoimmune Endocrinopathies. International Journal of Molecular Sciences, 2021, 22, 9879.	1.8	34
564	Clinical features, epidemiology, autoantibody status, HLA haplotypes and genetic mechanisms of type 1 diabetes mellitus among children in Qatar. Scientific Reports, 2021, 11, 18887.	1.6	7
565	Diabetes in Youth. Endocrinology and Metabolism Clinics of North America, 2021, 50, 491-512.	1.2	5
566	Improving Prediction of Risk for the Development of Type 1 Diabetesâ€™Insights From Populations at High Risk. Diabetes Care, 2021, , dci210018.	4.3	1
567	Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality. Frontiers in Immunology, 2021, 12, 737964.	2.2	33
568	Mistaken Identity: The Role of Autoantibodies in Endocrine Disease. journal of applied laboratory medicine, The, 2022, 7, 206-220.	0.6	2
569	Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes. Journal of Translational Autoimmunity, 2021, 4, 100089.	2.0	3
570	A longitudinal plasma lipidomics dataset from children who developed islet autoimmunity and type 1 diabetes. Scientific Data, 2018, 5, 180250.	2.4	23
571	Recognizing type 1 diabetes mellitus in children & adolescents. Nurse Practitioner, 2017, 42, 16-22.	0.2	2
575	A composite immune signature parallels disease progression across T1D subjects. JCI Insight, 2019, 4, .	2.3	15
576	Lipid mediators and biomarkers associated with type 1 diabetes development. JCI Insight, 2020, 5, .	2.3	15
577	Perinatal tolerance to proinsulin is sufficient to prevent autoimmune diabetes. JCI Insight, 2016, 1, e86065.	2.3	14

#	ARTICLE	IF	CITATIONS
578	A peripheral blood transcriptomic signature predicts autoantibody development in infants at risk of type 1 diabetes. JCI Insight, 2018, 3, .	2.3	18
579	Autoreactive T cells in type 1 diabetes. Journal of Clinical Investigation, 2017, 127, 2881-2891.	3.9	260
580	Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. Journal of Clinical Investigation, 2018, 128, 1888-1902.	3.9	43
581	Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study. PLoS Medicine, 2017, 14, e1002362.	3.9	90
582	A Rapid Lateral Flow Immunoassay for the Detection of Tyrosine Phosphatase-Like Protein IA-2 Autoantibodies in Human Serum. PLoS ONE, 2014, 9, e103088.	1.1	14
583	Islet Autoantibody Measurements from Dried Blood Spots on Filter Paper Strongly Correlate to Serum Levels. PLoS ONE, 2016, 11, e0166213.	1.1	5
584	Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. PLoS ONE, 2020, 15, e0242049.	1.1	22
585	Diabetes mellitus type 1 in childhood. Diabetes Mellitus, 2020, 23, 4-40.	0.5	14
586	Is It Time to Screen the General Population for Type 1 Diabetes?. US Endocrinology, 2015, 11, 10.	0.3	4
587	New insight into type 1 diabetes development: resolving early diabetogenic CD4+ T cell responses that precede seroconversion. Annals of Translational Medicine, 2018, 6, 58-58.	0.7	2
588	Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?. Current Diabetes Reviews, 2017, 13, 322-329.	0.6	25
589	Type 1 Diabetes-related Autoantibodies in Different Forms of Diabetes. Current Diabetes Reviews, 2019, 15, 199-204.	0.6	30
590	Alcoholic Neuropathy: Involvement of Multifaceted Signalling Mechanisms. Current Molecular Pharmacology, 2020, 14, 2-10.	0.7	9
592	LADY and MODY: How do we know them?. MedicÃna Pro Praxi, 2016, 13, 26-29.	0.0	2
593	Update on Genetic Determinants of Type1 Diabetes. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2016, 08, .	0.1	1
594	Type 1 diabetes mellitus and its oral tolerance therapy. World Journal of Diabetes, 2020, 11, 400-415.	1.3	9
595	PTPN22 and islet-specific autoimmunity: What have the mouse models taught us?. World Journal of Diabetes, 2017, 8, 330.	1.3	10
596	Pancreas Islet Cell-Specific Antibody Detection by ELISA. journal of applied laboratory medicine, The, 2022, 7, 66-74.	0.6	4

#	ARTICLE	IF	CITATIONS
598	Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. <i>Diabetes Care</i> , 2021, 44, 2449-2456.	4.3	73
599	A Humanized Mouse Strain That Develops Spontaneously Immune-Mediated Diabetes. <i>Frontiers in Immunology</i> , 2021, 12, 748679.	2.2	5
600	Four decades of the Bart ^o 's Oxford study: Improved tests to predict type 1 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14717.	1.2	8
601	Reduced Follicular Regulatory T Cells in Spleen and Pancreatic Lymph Nodes of Patients With Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, 2892-2902.	0.3	12
602	How benign autoimmunity becomes detrimental in type 1 diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	5
603	Detecting insulinitis in type 1 diabetes with ultrasound phase-change contrast agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	3
604	HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants. <i>Diabetologia</i> , 2022, 65, 88-100.	2.9	2
606	Typ-1-Diabetes. , 2014, , 57-106.		0
608	Inflammatory Pathways Linked to Beta Cell Demise in Diabetes. , 2014, , 1-50.		0
609	Immunology of Î²-Cell Destruction. , 2015, , 1047-1080.		0
610	Inflammatory Pathways Linked to Î² Cell Demise in Diabetes. , 2015, , 989-1045.		0
611	Successes and Disappointments with Clinical Islet Transplantation. , 2015, , 1245-1274.		0
612	An Immunologic Approach to the Pathogenesis of Type 1 Diabetes. <i>Global Journal of Pathology and Microbiology</i> , 2015, 2, 47-52.	0.0	0
614	Alternate Ways to Quantify Antibodies. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 854-856.	2.4	0
616	12.ÂDiabetes. , 2016, , .		0
617	The Prediction of Type 1 Diabetes Development and Diagnosis of Its Asymptomatic Phase Using Autoantibodies to Human Islets of Langerhans Long Before the Onset of the Disease. <i>MÃ-Ã¼narodnij EndokrinologÃ-Ã-nij Å½urnal</i> , 2016, .	0.1	0
618	Probiotics: Role in the Prevention of Chronic Viral Diseases. , 2017, , 61-81.		0
620	Prevention of Type 1 Diabetes. <i>Endocrinology</i> , 2018, , 451-463.	0.1	0

#	ARTICLE	IF	CITATIONS
621	Pathogenesis of Type 1 Diabetes. <i>Endocrinology</i> , 2018, , 141-179.	0.1	0
622	A Basic Review on Diabetes Mellitus. <i>Journal of Complementary and Alternative Medical Research</i> , 2018, 4, 1-15.	0.4	0
625	Definition, Diagnostic Criteria, Screening, Diagnosis, and Classification of Diabetes and Categories of Glucose Intolerance. , 2019, , 71-85.		1
626	Concentration of diabetes-associated autoantibodies against islet autoantigens (IA-2A, GADA, IAA), levels of basal and postprandial glycemia, and secretory state of basal and stimulated C-peptide in the preclinical period of type 1 diabetes development in children and adolescents as immunological, metabolic and hormonal predictors of the clinical onset of the disease. <i>Journal of the National Academy of Medical Sciences of Ukraine</i> , 2019, ,	0.1	0
627	Current advances in clinical pathophysiology in the study of the pathogenesis of type 1 and type 2 diabetes mellitus in humans. <i>МАНародний Ендокринологічний Журнал</i> , 2019, 15, 422-434.	0.1	2
628	Neuroendocrine and Biobehavioral Influences on Diabetes in Youth. , 2020, , 19-31.		0
629	Possible Kefir Biological Effects: 4: Effect of Kefir Beverage on The Histopathological and Macroscopical Changes in Adipose Tissue of High Fat-Fed STZ- Induced Diabetic Male Wistar Rat. <i>Egyptian Academic Journal of Biological Sciences C Physiology and Molecular Biology</i> , 2020, 12, 51-63.	0.0	1
630	Activated but functionally impaired memory Tregs are expanded in slow progressors to type 1 diabetes. <i>Diabetologia</i> , 2022, 65, 343-355.	2.9	9
631	Integrated Analysis of the Pancreas and Islets Reveals Unexpected Findings in Human Male With Type 1 Diabetes. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab162.	0.1	0
632	The role of gluten in multiple sclerosis, psoriasis, autoimmune thyroid diseases and type 1 diabetes. , 2022, , 223-246.		0
634	Prediction of the uncontrolled course of autoimmune type 1 diabetes in children. <i>ZdorovĚe Rebenka</i> , 2020, 15, 69-78.	0.0	0
636	General population screening for childhood type 1 diabetes: is it time for a UK strategy?. <i>Archives of Disease in Childhood</i> , 2022, 107, 790-795.	1.0	8
637	Autoantibodies to N-terminally Truncated GAD65(96-585): HLA Associations and Predictive Value for Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e935-e946.	1.8	6
638	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. <i>Frontiers in Endocrinology</i> , 2021, 12, 764138.	1.5	22
641	Labs Related to Glucose Metabolism and Diabetes. , 2021, , 181-184.		0
644	Protein Glycosylation in Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1325, 285-305.	0.8	6
645	Association of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1510-e1517.	1.8	3
646	Establishing reference intervals for islet autoantibodies in Han Chinese type 1 diabetes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2021, , 1-8.	0.6	0

#	ARTICLE	IF	CITATIONS
647	Heterogeneity of Diabetes: Î²-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Researchâ€™s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Healthâ€™s National Institute of Diabetes and Digestive and Kidney Diseases. <i>Diabetes</i> , 2022, 71, 1-22.	0.3	8
648	100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes. <i>Immunotherapy Advances</i> , 2021, 1, Itab024.	1.2	2
649	Heterogeneity of Diabetes: Î²-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Researchâ€™s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Healthâ€™s National Institute of Diabetes and Digestive and Kidney Diseases. <i>Diabetes Care</i> , 2022, 45, 3-22.	4.3	14
650	Exocrine pancreas function is impaired in adult relatives of patients with type 1 diabetes. <i>Acta Diabetologica</i> , 2022, 59, 473-479.	1.2	3
651	Supplementation with <i>Bifidobacterium longum</i> subspecies <i>infantis</i> EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. <i>BMJ Open</i> , 2021, 11, e052449.	0.8	15
652	Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in Children. <i>Diabetes Care</i> , 2022, 45, 160-168.	4.3	8
653	Heterogeneity of Diabetes: Î²-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Researchâ€™s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Healthâ€™s National Institute of Diabetes and Digestive and Kidney Diseases. <i>Canadian Journal of Diabetes</i> , 2021, 45, 697-713.	0.4	2
654	Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 311-318.	4.3	11
655	Clinical study of autoantibodies in type 1 diabetes mellitus children with ketoacidosis or microalbuminuria. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 36, e24164.	0.9	1
656	PrimÃrprÃvention: Diabetes Typ 1: Wie ist der Stand der Insulinimpfung?. , 0, , .		0
659	Automation of a multiplex agglutination-PCR (ADAP) type 1 diabetes (T1D) assay for the rapid analysis of islet autoantibodies. <i>SLAS Technology</i> , 2022, 27, 26-31.	1.0	5
660	2. Classification and Diagnosis of Diabetes:â€™Standards of Medical Care in Diabetesâ€™2022â€™. <i>Diabetes Care</i> , 2022, 45, S17-S38.	4.3	1,106
661	Glucose biosensors in clinical practice: principles, limits and perspectives of currently used devices. <i>Theranostics</i> , 2022, 12, 493-511.	4.6	52
662	Cytotoxicity-Related Gene Expression and Chromatin Accessibility Define a Subset of CD4+ T Cells That Mark Progression to Type 1 Diabetes. <i>Diabetes</i> , 2022, 71, 566-577.	0.3	2
663	Pathogenic Mechanism of Autoimmune Diabetes Mellitus in Humans: Potential Role of Streptozotocin-Induced Selective Autoimmunity against Human Islet Î²-Cells. <i>Cells</i> , 2022, 11, 492.	1.8	6
664	Prediction of autoimmune diseases: From bench to bedside. , 2022, , 425-450.		0
666	The Prevalence of Islet Autoantibodies in Children and Adolescents With Type 1 Diabetes Mellitus: A Global Scoping Review. <i>Frontiers in Endocrinology</i> , 2022, 13, 815703.	1.5	17
667	Type 1 diabetes mellitus in pediatric age group: A rising endemic. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 27.	0.3	5

#	ARTICLE	IF	CITATIONS
687	Heterogeneity in the presentation of clinical type 1 diabetes defined by the level of risk conferred by human leukocyte antigen class II genotypes. <i>Pediatric Diabetes</i> , 2022, 23, 219-227.	1.2	5
688	Heterogeneity of beta-cell function in subjects with multiple islet autoantibodies in the TEDDY family prevention study - TEFA. <i>Clinical Diabetes and Endocrinology</i> , 2021, 7, 23.	1.3	1
689	Immunotherapy for type 1 diabetes. <i>British Medical Bulletin</i> , 2021, 140, 76-90.	2.7	9
690	CGM Metrics Predict Imminent Progression to Type 1 Diabetes: Autoimmunity Screening for Kids (ASK) Study. <i>Diabetes Care</i> , 2022, 45, 365-371.	4.3	25
692	Autoimmunity and psychosis. , 2022, , 343-365.		1
693	Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , .	0.9	0
694	Understanding the Mechanism of Diabetes Mellitus in a LRBA-Deficient Patient. <i>Biology</i> , 2022, 11, 612.	1.3	0
695	Viral infectionâ€related gene upregulation in monocytes in children with signs of Î²â€cell autoimmunity. <i>Pediatric Diabetes</i> , 2022, 23, 703-713.	1.2	3
711	Early Surveillance for Autoimmune diabetes: protocol for a qualitative study of general population and stakeholder perspectives on screening for type 1 diabetes in the UK (ELSA 1). <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002750.	1.2	6
712	Predicting age at onset of type 1 diabetes in children using regression, artificial neural network and Random Forest: A case study in Saudi Arabia. <i>PLoS ONE</i> , 2022, 17, e0264118.	1.1	3
713	Simulating Screening for Risk of Childhood Diabetes: The Collaborative Open Outcomes tool (COOL).. AMIA ... Annual Symposium proceedings, 2021, 2021, 516-525.	0.2	0
715	Ultrasound Imaging of Pancreatic Perfusion Dynamics Predicts Therapeutic Prevention of Diabetes in Preclinical Models of Type 1 Diabetes. <i>Ultrasound in Medicine and Biology</i> , 2022, , .	0.7	1
716	The heterogeneity of type 1 diabetes: From immunopathology to immune intervention. , 2022, , 83-104.		6
718	Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	1
719	Association of HLA-DQ Heterodimer Residues âˆ²18Î² and Î²57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trialâ€Type 1. <i>Diabetes Care</i> , 2022, 45, 1610-1620.	4.3	1
720	Î± Cell dysfunction in islets from nondiabetic, glutamic acid decarboxylase autoantibodyâ€positive individuals. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	24
721	Exploring Minimally Invasive Approach to Define Stages of Type 1 Diabetes Remotely. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 655-665.	2.4	2
722	Changes in the Coexpression of Innate Immunity Genes During Persistent Islet Autoimmunity Are Associated With Progression of Islet Autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY). <i>Diabetes</i> , 2022, 71, 2048-2057.	0.3	3

#	ARTICLE	IF	CITATIONS
723	Islet autoantibody seroconversion in type-1 diabetes is associated with metagenome-assembled genomes in infant gut microbiomes. <i>Nature Communications</i> , 2022, 13, .	5.8	8
724	Multi-Faceted Influence of Obesity on Type 1 Diabetes in Children – From Disease Pathogenesis to Complications. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7
725	Recent information on test utilization and intraindividual change in anti-glutamic acid decarboxylase antibody in Korea: a retrospective study. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002739.	1.2	0
726	Differentially methylated and expressed genes in familial type 1 diabetes. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
727	Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	27
728	Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 589-596.	5.5	16
729	<sc>INnoVative</sc> trial design for testing the Efficacy, Safety, and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 <sc>Diabetes</sc> in autoantibody positive participants: a protocol for three parallel double-blind randomised controlled trials () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 492 Td (<sc>	1.2	2
731	Transcriptional regulatory networks of circulating immune cells in type 1 diabetes: A community knowledgebase. <i>IScience</i> , 2022, 25, 104581.	1.9	3
732	Antigen-specific immunotherapies in type 1 diabetes. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 73, 127040.	1.5	7
734	Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies. <i>Diabetologia</i> , 0, , .	2.9	5
735	A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	35
736	First-emerging islet autoantibody and glucose metabolism: search for type 1 diabetes subtypes. <i>Endocrine Connections</i> , 2022, , .	0.8	0
737	Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S49-S79.	0.6	1
738	Circular RNAs in diabetes mellitus and its complications. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	19
739	Temporal development of T cell receptor repertoires during childhood in health and disease. <i>JCI Insight</i> , 2022, 7, .	2.3	2
740	Natural history of type 1 diabetes on an immunodysregulatory background with genetic alteration in B-cell activating factor receptor: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
741	Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. <i>Diabetologia</i> , 2022, 65, 2121-2131.	2.9	15
742	Possible Relationship between the HLA-DRA1 Intron Haplotype of Three Single-Nucleotide Polymorphisms in Intron 1 of the HLA-DRA1 Gene and Autoantibodies in Children at Increased Genetic Risk for Autoimmune Type 1 Diabetes. <i>ImmunoHorizons</i> , 2022, 6, 614-629.	0.8	0

#	ARTICLE	IF	CITATIONS
743	The etiology and pathogenesis of type 1 diabetes – A personal, non-systematic review of possible causes, and interventions. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
744	Precision medicine in type 1 diabetes. <i>Diabetologia</i> , 2022, 65, 1854-1866.	2.9	18
745	Clinical and experimental treatment of type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2022, 210, 105-113.	1.1	4
746	The relationship between GAD65 autoantibody and the risk of T1DM onset. <i>Journal of Diabetes and Metabolic Disorders</i> , 0, , .	0.8	0
747	Precision Medicine in Endocrinology Practice. , 2022, , 67-91.		0
748	Rising Hemoglobin A1c in the Nondiabetic Range Predicts Progression of Type 1 Diabetes As Well As Oral Glucose Tolerance Tests. <i>Diabetes Care</i> , 2022, 45, 2342-2349.	4.3	4
749	Predictors of the Initiation of Islet Autoimmunity and Progression to Multiple Autoantibodies and Clinical Diabetes: The TEDDY Study. <i>Diabetes Care</i> , 2022, 45, 2271-2281.	4.3	21
750	HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children. <i>Pediatric Diabetes</i> , 2022, 23, 1586-1593.	1.2	3
752	Diabetes-related antibody-testing is a valuable screening tool for identifying monogenic diabetes - a survey from the worldwide SWEET registry. <i>Diabetes Research and Clinical Practice</i> , 2022, , 110110.	1.1	0
753	Hypothesis: Induction of Autoimmunity in Type 1 Diabetes – A Lipid Focus. <i>Diabetes</i> , 2022, 71, 2067-2074.	0.3	3
754	<sc>ISPAD</sc> Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2022, 23, 1175-1187.	1.2	35
755	Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 2099-2117.	0.5	7
756	Early glucose metabolism in children at risk for type 1 diabetes based on islet autoantibodies compared to low-risk control groups. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
757	Islet Autoantibody Levels Differentiate Progression Trajectories in Individuals With Presymptomatic Type 1 Diabetes. <i>Diabetes</i> , 2022, 71, 2632-2641.	0.3	3
758	Comparative analysis of the repertoire of insulin-reactive B cells in type 1 diabetes-prone and resistant mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
759	Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes. <i>Diabetologia</i> , 2023, 66, 132-146.	2.9	6
760	Recognition of mRNA Splice Variant and Secretory Granule Epitopes by CD4+ T Cells in Type 1 Diabetes. <i>Diabetes</i> , 2023, 72, 85-96.	0.3	3
761	Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in children. <i>Diabetologia</i> , 2023, 66, 93-104.	2.9	6

#	ARTICLE	IF	CITATIONS
762	The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants. <i>Clinical and Experimental Immunology</i> , 2022, 210, 151-162.	1.1	6
763	Dysregulation of secondary bile acid metabolism precedes islet autoimmunity and type 1 diabetes. <i>Cell Reports Medicine</i> , 2022, 3, 100762.	3.3	9
764	Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in <sc>A</sc> ustralia and <sc>N</sc> ew <sc>Z</sc> ealand. <i>Pediatric Diabetes</i> , 2022, 23, 1594-1601.	1.2	6
765	New therapeutic approaches for type 1 diabetes: Disease-modifying therapies. <i>World Journal of Diabetes</i> , 0, 13, 835-850.	1.3	6
766	Type 1 Diabetes: Current Advances in High-Throughput Technologies and Computational Biology for Biomarker Studies. , 0, , .		0
767	Persistence of Î²-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening. <i>Diabetes Care</i> , 0, , .	4.3	3
768	Molar-incisor hypomineralisation prevalence in a cohort of Australian children with type 1 diabetes. <i>European Archives of Paediatric Dentistry: Official Journal of the European Academy of Paediatric Dentistry</i> , 0, , .	0.7	0
769	Zinc transporter 8 haploinsufficiency protects against beta cell dysfunction in type 1 diabetes by increasing mitochondrial respiration. <i>Molecular Metabolism</i> , 2022, 66, 101632.	3.0	3
770	Estimating the total incidence of type 1 diabetes in children and adolescents aged 0â€“19 years from 1990 to 2050: a global simulation-based analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 848-858.	5.5	19
771	Immunological markers in type 1 diabetes mellitus in Thi-Qar province, southern Iraq. <i>Journal of Medicine and Life</i> , 2022, 15, 1234-1239.	0.4	1
772	Affinity purification of serum-derived anti-IA-2 autoantibodies in type 1 diabetes using a novel MBP-IA-2 fusion protein. <i>Biochemistry and Biophysics Reports</i> , 2023, 33, 101413.	0.7	0
773	Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering. <i>Diabetologia</i> , 0, , .	2.9	4
774	Î²-Cell Function and Insulin Sensitivity in Youth With Early Type 1 Diabetes From a 2-Hour 7-Sample OGTT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1376-1386.	1.8	2
775	Combined detection of islet autoantibodies for clinical diagnosis of type 1 diabetes in the low-prevalence population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	1.8	0
777	2. Classification and Diagnosis of Diabetes: <i>Standards of Care in Diabetesâ€”2023</i>. <i>Diabetes Care</i> , 2023, 46, S19-S40.	4.3	534
778	Autoimmune reaction against pancreatic beta cells in children and adolescents with simple obesity. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
779	The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes. <i>Diabetologia</i> , 2023, 66, 508-519.	2.9	4
780	<sc>ISPAD</sc> Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents. <i>Pediatric Diabetes</i> , 2022, 23, 1160-1174.	1.2	40

#	ARTICLE	IF	CITATIONS
782	<i>CTLA4</i>, <i>SH2B3</i> and <i>CLEC16A</i> diversely affect the progression of early islet autoimmunity in relatives of type 1 diabetes patients. <i>Clinical and Experimental Immunology</i> , 0, , .	1.1	0
783	A Monovalent Mt10-CVB3 Vaccine Prevents CVB4-Accelerated Type 1 Diabetes in NOD Mice. <i>Vaccines</i> , 2023, 11, 76.	2.1	5
784	Genetic determinants of type 1 diabetes in individuals with weak evidence of islet autoimmunity at disease onset. <i>Diabetologia</i> , 2023, 66, 695-708.	2.9	0
785	Effective assay technologies fit for large-scale population screening of type 1 diabetes. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 0, 3, .	0.3	3
786	Kynurenine Pathway in Diabetes Mellitusâ€”Novel Pharmacological Target?. <i>Cells</i> , 2023, 12, 460.	1.8	23
787	Difference in the early clinical course between children with type 1 diabetes having a single antibody and those having multiple antibodies against pancreatic Î²-cells. <i>Endocrine Journal</i> , 2023, , .	0.7	0
788	A perspective on treating type 1 diabetes mellitus before insulin is needed. <i>Nature Reviews Endocrinology</i> , 0, , .	4.3	2
790	Type 1 diabetes. <i>Lancet, The</i> , 2023, 401, 2149-2162.	6.3	29
791	The role of endoplasmic reticulum aminopeptidases in type 1 diabetes mellitus. <i>Life Sciences</i> , 2023, 323, 121701.	2.0	1
792	Vaccines against Group B Coxsackieviruses and Their Importance. <i>Vaccines</i> , 2023, 11, 274.	2.1	3
793	Plasma-derived exosomal miRNAs as potentially novel biomarkers for latent autoimmune diabetes in adults. <i>Diabetes Research and Clinical Practice</i> , 2023, 197, 110570.	1.1	1
794	The prevalence of diabetes and thyroid related autoantibodies in Sri Lankan children with type 1 diabetes and their unaffected siblings â€” The utility of a new screening assay. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
796	Predicting the development of T1D and identifying its Key Performance Indicators in children; a case-control study in Saudi Arabia. <i>PLoS ONE</i> , 2023, 18, e0282426.	1.1	2
798	Refining the Definition of Stage 1 Type 1 Diabetes: An Ontology-Driven Analysis of the Heterogeneity of Multiple Islet Autoimmunity. <i>Diabetes Care</i> , 2023, 46, 1753-1761.	4.3	2
800	Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases: Workshop Proceedings. <i>Diabetes</i> , 2023, 72, 433-448.	0.3	2
801	SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study. <i>Lancet Diabetes and Endocrinology</i> ,the, 2023, 11, 251-260.	5.5	20
803	Infant gut microbiome composition correlated with type 1 diabetes acquisition in the general population: the ABIS study. <i>Diabetologia</i> , 2023, 66, 1116-1128.	2.9	12
804	HLAâ€”DQâ€”conferred risk for type 1 diabetes does not alter neutralizing antibody response to a widely used enterovirus vaccine, the poliovirus vaccine. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1

#	ARTICLE	IF	CITATIONS
805	What does the licensing of teplizumab mean for diabetes care?. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2051-2057.	2.2	0
806	T peripheral helper cells in autoimmune diseases: What do we know?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
807	Teplizumab â€“ preventative approaches to type 1 diabetes mellitus. <i>Practical Diabetes</i> , 2023, 40, 35.	0.1	1
808	Type 1 Diabetes. , 2023, , 909-918.		0
809	Protocol for a nested case-control study design for omics investigations in the Environmental Determinants of Islet Autoimmunity cohort. <i>Annals of Medicine</i> , 2023, 55, .	1.5	1
812	Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases. <i>Pancreas</i> , 2022, 51, 1061-1073.	0.5	3
813	What is the role of puberty in the development of islet autoimmunity and progression to type 1 diabetes?. <i>European Journal of Epidemiology</i> , 2023, 38, 689-697.	2.5	0
819	Pathophysiology, Diagnosis, and Management o Autoimmune Polyglandular Syndromes in Childhood and Adolescence. <i>Endocrinology</i> , 2023, , 1-46.	0.1	0
822	Definition, Diagnostic Criteria, Screening, Diagnosis, and Classification of Diabetes and Categories of Glucose Intolerance: An Update. , 2023, , 89-103.		0
823	Diabetes in Children and Adolescents. , 2023, , 1063-1094.		0
841	The countdown to type 1 diabetes: when, how and why does the clock start?. <i>Diabetologia</i> , 2023, 66, 1169-1178.	2.9	4
845	Utility of genetic risk scores in type 1 diabetes. <i>Diabetologia</i> , 2023, 66, 1589-1600.	2.9	3
850	Islet autoimmunity in human type 1 diabetes: initiation and progression from the perspective of the beta cell. <i>Diabetologia</i> , 2023, 66, 1971-1982.	2.9	1
852	Diabetes in the Tropics. , 2024, , 879-885.		0
869	Recurrence of Type 1 Diabetes Mellitus. , 2023, , 781-797.		0
870	Epidemiology and Pathogenesis of Type 1 Diabetes. , 2023, , 13-39.		0
872	Inflammation and Diabetes Mellitus. <i>Contemporary Endocrinology</i> , 2023, , 55-77.	0.3	0
878	Mechanisms and consequences of sex differences in immune responses. <i>Nature Reviews Nephrology</i> , 2024, 20, 37-55.	4.1	4

#	ARTICLE	IF	CITATIONS
888	Autoimmune diseases: targets, biology, and drug discovery. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	1
891	The Story of Diabetes and its Causes. , 2023, , 1-30.		0
903	Type 1 diabetes pathogenesis: lessons learned and remaining questions. , 2023, , 87-106.		0
906	The immunology of type 1 diabetes. <i>Nature Reviews Immunology</i> , 0, , .	10.6	0